"","Drug","Targets","Disease","Enrichment.biomarker","Marker.type","Biomarker.relationship","Model","PMID","Article.title","Key.sentence","Pubmed.link","Note","Biomarker.logical.conditions","drug_drugbank_standard","drug_pubchem","biomarker_ensembl_standard","diseases_EFO_MONDO_standard","biomarker_term","QC"
"1","NA","NA","LIVER CANCER","ACVR2B-As1","RNA",NA,"Patients",31886217,"Investigation of the Clinical Significance and Prognostic Value of the lncRNA ACVR2B-As1 in Liver Cancer.","Higher ACVR2B-AS1 expression is an independent adverse prognostic factor for overall survival (OS) and relapse-free survival (RFS) in liver cancer patients.","https://www.ncbi.nlm.nih.gov/pubmed/31886217","High_Unfavourable",NA,"NA","56956252","ENSG00000229589","MONDO_0002691","ACVR2B-AS1 RNA NA","pass"
"2","NA","NA","LIVER CANCER","MAST2","expression",NA,"Patients",31882722,"High MAST2 mRNA expression and its role in diagnosis and prognosis of liver cancer.","High MAST2 expression was associated with advanced clinical status such as histological type (p = 0.0059), histologic grade (p = 0.0142), stage (p = 0.0008), T classification (p = 0.0028), N classification (p = 0.0107), survival status (p = 0.0062), and poor prognosis of patients.MAST2 is a potential diagnostic and prognostic biomarker of liver cancer","https://www.ncbi.nlm.nih.gov/pubmed/31882722","High_Unfavourable",NA,"NA","56956252","ENSG00000086015","MONDO_0002691","MAST2 EXPRESSION NA","pass"
"3","NA","NA","HBV-RELATED HEPATOCELLULAR CARCINOMA","IGF2AS","serum-level",NA,"Patients",31850718,"Long Non-Coding RNA IGF2AS in Serum may be a Biomarker for Diagnosis of Hepatitis B Virus-Related Hepatocellular Carcinoma.","level of IGF2AS in liver cancer tissues of HBV-related HCC was significantly higher than that in the adjacent non-cancerous tissues. serum IGF2AS may be a potential biomarker for the diagnosis of HBV-related HCC","https://www.ncbi.nlm.nih.gov/pubmed/31850718","High_Unfavourable",NA,"NA","56956252","NA","EFO_0000349","IGF2AS SERUM-LEVEL NA","failed biomarker"
"4","NA","NA","HEPATOCELLULAR CARCINOMA","IL13RA2","expression",NA,"celline",31823484,"Silencing of IL13RA2 promotes partial epithelial-mesenchymal transition in hepatocellular carcinoma via ERK signaling pathway activation.","low expression of IL13RA2 is associated with poor survival of patients with HCC, and demonstrated that IL13RA2 knockdown endows HCC cells with invasive potential.IL13RA2 may have potential as a prognostic biomarker for HCC.","https://www.ncbi.nlm.nih.gov/pubmed/31823484","Low_Unfavourable",NA,"NA","56956252","ENSG00000123496","EFO_0000182","IL13RA2 EXPRESSION NA","pass"
"5","NA","NA","LIVER CANCER","PES1","expression",NA,"Patients",31814761,"PES1 In Liver Cancer: A Prognostic Biomarker With Tumorigenic Roles.","PES1 was upregulated in liver cancer and correlated with poor prognosis, by promoting tumor cell proliferation, migration, and invasion, and PES1 may be a novel diagnostic and prognostic bio-marker and a promising therapeutic target in liver cancer.","https://www.ncbi.nlm.nih.gov/pubmed/31814761","High_Unfavourable",NA,"NA","56956252","ENSG00000100029","MONDO_0002691","PES1 EXPRESSION NA","pass"
"6","NA","NA","INTRAHEPATIC CHOLANGIOCARCINOMA","CXCL9","expression",NA,"Mouse",31799781,"Endogenous CXCL9 affects prognosis by regulating tumor-infiltrating natural killer cells in intrahepatic cholangiocarcinoma.","CXCL9-sufficient cells were less tumorigenic in the liver than CXCL9-deficient cells in mice. CXCL9 was useful as a prognostic marker.CXCL9 upregulation might offer a therapeutic strategy for treating CXCL9-expressing iCCA","https://www.ncbi.nlm.nih.gov/pubmed/31799781","Low_Unfavourable",NA,"NA","56956252","ENSG00000138755","EFO_1001961","CXCL9 EXPRESSION NA","pass"
"7","NA","NA","HEPATOCELLULAR CARCINOMA","RASSF1A,                            E-Cadherin,RUNX3","methylation,methylation,methylation",NA,"Patients",31790342,"Methylation of tumour suppressor genes RUNX3, RASSF1A and E-Cadherin in HCV-related liver cirrhosis and hepatocellular carcinoma.","The presence of hypermethylated serum RASSF1A, E-Cadherin and RUNX3 is linked to HCC in patients with HCV-related cirrhosis. Only E-Cadherin is an independent risk factor for prediction of HCC with low AFP. These findings may be of diagnostic value.","https://www.ncbi.nlm.nih.gov/pubmed/31790342","High_Unfavourable",NA,"NA","56956252","NA, ENSG00000039068, ENSG00000020633","EFO_0000182","failed","failed biomarker,failed term"
"8","NA","NA","HEPATOCELLULAR CARCINOMA","PD1,TIM3","expression,expression",NA,"Patients",31783783,"PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma.","PD1Hi or TIM3+PD1Hi CD8+ T cells were significantly correlated with poor prognosis, and the latter was positioned in close proximity to PD-L1+ tumor associated macrophages. exhausted T cells could act as a biomarker to select the most care-demanding patients for tailored therapies.","https://www.ncbi.nlm.nih.gov/pubmed/31783783","High_Unfavourable",NA,"NA","56956252","ENSG00000145335, ENSG00000135077","EFO_0000182","failed","failed term"
"9","NA","NA","HEPATOCELLULAR CARCINOMA","LARP4B","expression",NA,"Patients",31772683,"Expression of La Ribonucleoprotein Domain Family Member 4B (LARP4B) in Liver Cancer and Their Clinical and Prognostic Significance.","liver cancer patients with high LARP4B expression had shorter overall/relapse-free survival.LARP4B is a potential independent biomarker for diagnosis and prognosis in liver cancer patients.","https://www.ncbi.nlm.nih.gov/pubmed/31772683","High_Unfavourable",NA,"NA","56956252","ENSG00000107929","EFO_0000182","LARP4B EXPRESSION NA","pass"
"10","NA","NA","HEPATOCELLULAR CARCINOMA","PAR2","expression",NA,"Patients",31768188,"Increased expression of protease-activated receptors 2 indicates poor prognosis in HBV related hepatocellular carcinoma.","PAR2 expression was increased in HCC. High PAR2 expression was correlated with both decreased overall survival and disease-free survival in patients with HCC. High PAR2 expression indicated a poor prognosis.","https://www.ncbi.nlm.nih.gov/pubmed/31768188","High_Unfavourable",NA,"NA","56956252","ENSG00000164251","EFO_0000182","PAR2 EXPRESSION NA","pass"
"11","NA","NA","LIVER CANCER","TIPRL,LC3,CD133","expression,expression,expression",NA,"Tissues",31727942,"The positive correlation of TIPRL with LC3 and CD133 contributes to cancer aggressiveness: potential biomarkers for early liver cancer.","TIPRL knockdown significantly reduced expressions of LC3, CD133, stemness-related genes, as well as viability and stemness of liver cancer cell-lines.complex involvement of TIPRL/LC3/CD133 in liver cancer aggressiveness can together or individually serve as potential biomarkers for the early detection of liver cancer.","https://www.ncbi.nlm.nih.gov/pubmed/31727942","High_Unfavourable,High_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000143155, ENSG00000140941, ENSG00000007062","MONDO_0002691","failed","failed term"
"12","NA","NA","HEPATOCELLULAR CARCINOMA","miR-942,RRM2B","RNA,expression",NA,"Tissues",31632084,"miR-942 promotes proliferation and metastasis of hepatocellular carcinoma cells by inhibiting RRM2B.","High expression of miR-942 was associated with shorter overall survival and disease-free survival time of HCC patients. RRM2B was validated as a target gene of miR-942.miR-942 may serve as a potential biomarker for HCC and its inhibitor may be a therapeutic agent for the treatment of this deadly disease.","https://www.ncbi.nlm.nih.gov/pubmed/31632084","High_Unfavourable",NA,"NA","56956252","NA, ENSG00000048392","EFO_0000182","failed","failed biomarker,failed term"
"13","NA","NA","HEPATOCELLULAR CARCINOMA","AKR1C1-3 ","expression",NA,"Patients",31611960,"AKR1C1-3, notably AKR1C3, are distinct biomarkers for liver cancer diagnosis and prognosis: Database mining in malignancies.","high expression levels of AKR1C1-3 were correlated with lower overall survival in liver cancer patients. Using the co-expression and PPI network, AKR1C1-3 genes were identified that were involved in the same pathway displaying 44 total unique interactors. These results suggested that the increased AKR1C1-3, notably AKR1C3 expression levels served as possible diagnostic biomarkers and essential prognostic factors for liver cancer patients.","https://www.ncbi.nlm.nih.gov/pubmed/31611960","High_Unfavourable",NA,"NA","56956252","NA","EFO_0000182","AKR1C1-3 EXPRESSION NA","failed biomarker"
"14","NA","NA","HEPATOCELLULAR CARCINOMA","KCNK2,KCNK15,KCNK17,KCNK9","expression",NA,"Patients",31581133,"KCNK levels are prognostic and diagnostic markers for hepatocellular carcinoma.","reduced expression of KCNK2, KCNK15, and KCNK17 in liver cancer, as well as overexpression of KCNK9, all of which correlated with a better prognosis for HCC patients per survival analyses.","https://www.ncbi.nlm.nih.gov/pubmed/31581133","Low_favourable,Low_favourable,Low_favourable,High_favourable",NA,"NA","56956252","ENSG00000082482, ENSG00000124249, ENSG00000124780, ENSG00000169427","EFO_0000182","failed","failed term"
"15","NA","NA","HEPATOCELLULAR CARCINOMA","CTHRC1","expression",NA,"Tissues",31576140,"CTHRC1 May Serve As A Prognostic Biomarker For Hepatocellular Carcinoma.","High expression of CTHRC1 in hepatocellular carcinoma tissues is significantly associated with poor survival.","https://www.ncbi.nlm.nih.gov/pubmed/31576140","High_Unfavourable",NA,"NA","56956252","ENSG00000164932","EFO_0000182","CTHRC1 EXPRESSION NA","pass"
"16","NA","NA","HEPATOCELLULAR CARCINOMA","CDCA5","expression",NA,"Patients",30497429,"CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC).","increased CDCA5 expression was associated with increased tumor diameter and microvascular invasion in HCC.","https://www.ncbi.nlm.nih.gov/pubmed/30497429","High_Unfavourable",NA,"NA","56956252","ENSG00000146670","EFO_0000182","CDCA5 EXPRESSION NA","pass"
"17","NA","NA","HEPATOCELLULAR CARCINOMA","CPEB1,SIRT1","expression,expression",NA,"NA",30237545,"CPEB1 mediates hepatocellular carcinoma cancer stemness and chemoresistance.","CPEB1 is downregulated in HCC.Overexpression of CPEB1 dramatically reduced HCC cell stemness, whereas silencing CPEB1 enhances it.negative regulation between CPEB1 and SIRT1 contributes to the suppression of cancer stemness in HCC","https://www.ncbi.nlm.nih.gov/pubmed/30237545","High_Unfavourable,Low_Unfavourable",NA,"NA","56956252","ENSG00000214575, ENSG00000096717","EFO_0000182","failed","failed term"
"18","NA","NA","HEPATOCELLULAR CARCINOMA","MTHFD1,AFP","expression,expression",NA,"NA",30997850,"Overexpression of MTHFD1 in hepatocellular carcinoma predicts poorer survival and recurrence.","High MTHFD1 expression in HCC represented poor prognosis. Combining MTHFD1 with serum AFP, survival analysis demonstrated the prognosis of the MTHFD1 low expression and AFP ≤20 ng/ml group was better ","https://www.ncbi.nlm.nih.gov/pubmed/30997850","High_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000100714, ENSG00000081051","EFO_0000182","failed","failed term"
"19","NA","NA","HEPATOCELLULAR CARCINOMA","HOXD8","expression",NA,"celline",30941968,"MiR-5692a promotes proliferation and inhibits apoptosis by targeting HOXD8 in hepatocellular carcinoma.","overexpressed miR-5692a accelerated cell cycle and inhibited cell apoptosis.miR-5692a functioned as an oncogene by regulating HOXD8 in HCC.","https://www.ncbi.nlm.nih.gov/pubmed/30941968","High_Unfavourable",NA,"NA","56956252","ENSG00000175879","EFO_0000182","HOXD8 EXPRESSION NA","pass"
"20","NA","NA","HEPATOCELLULAR CARCINOMA,HEPATOBLASTOMA","OGDHL","expression/methylation",NA,"PDX,Patients",31899205,"OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.","silencing of OGDHL contributed to HCC development and survival by regulating glutamine metabolic pathways, and suggest OGDHL as a promising prognostic biomarker and therapeutic target for HCC.","https://www.ncbi.nlm.nih.gov/pubmed/31899205","Low_Unfavourable",NA,"NA","56956252","ENSG00000197444","EFO_0000707","OGDHL EXPRESSION/METHYLATION NA","pass"
"21","NA","NA","HEPATOCELLULAR CARCINOMA","TIA1,EP400","expression,expression",NA,"in silico",31897208,"In silico identification of EP400 and TIA1 as critical transcription factors involved in human hepatocellular carcinoma relapse.","high expression of EP400 and TIA1 were significantly associated with shorter relapse-free survival and disease-free survival of patients with HCC.  high EP400 expression significantly reduced the overall survival of patients with HCC. EP400 and TIA1 may therefore serve as potential prognostic and therapeutic biomarkers.","https://www.ncbi.nlm.nih.gov/pubmed/31897208","High_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000116001, ENSG00000183495","EFO_0000182","failed","failed term"
"22","NA","NA","HEPATOCELLULAR CARCINOMA","UBE2Z","expression",NA,"Patients",31831168,"Upregulation of ubiquitin-conjugating enzyme E2Z is associated with human hepatocellular carcinoma","High UBE2Z expression was significantly correlated with age, advanced TNM stage, histological grade, vascular invasion, elevated serum alpha-fetoprotein expression (AFP), worse overall survival (OS) and disease-free survival (DFS) of HCC patients .UBE2Z might be considered as a prognostic biomarker in HCC and provided a potential therapeutic tumor-associated antigen for HCC.","https://www.ncbi.nlm.nih.gov/pubmed/31831168","High_Unfavourable",NA,"NA","56956252","ENSG00000159202","EFO_0000182","UBE2Z EXPRESSION NA","pass"
"23","NA","NA","HEPATOCELLULAR CARCINOMA","APOF","expression",NA,"celline",31687155,"Decreased expression of ApoF associates with poor prognosis in human hepatocellular carcinoma.","ApoF expression was down-regulated in HCC, which was associated with low recurrence-free survival rate. ApoF may serve as a tumor suppressor in HCC and be a potential application for the treatment of this disease.","https://www.ncbi.nlm.nih.gov/pubmed/31687155","Low_Unfavourable",NA,"NA","56956252","ENSG00000175336","EFO_0000182","APOF EXPRESSION NA","pass"
"24","NA","NA","HEPATOCELLULAR CARCINOMA","AKR1B10","serum-level",NA,"Patients",31495535,"Serum AKR1B10 predicts the risk of hepatocellular carcinoma - A retrospective single-center study.","The level of serum AKR1B10 was significantly higher in HCC patients (1800.24±2793.79) than in health donors (129.34±194.129), and downregulation of serum AKR1B10 in HCC patients was observed after hepatectomy. ","https://www.ncbi.nlm.nih.gov/pubmed/31495535","High_unfavourable",NA,"NA","56956252","ENSG00000198074","EFO_0000182","AKR1B10 SERUM-LEVEL NA","pass"
"25","CISPLATIN","NA","HEPATOBLASTOMA","CSF3R","DNA hypermethylation",NA,"Patients",31894653,"Hypermethylation of CSF3R Is a Novel Cisplatin Resistance Marker and Predictor of Response to Postoperative Chemotherapy in Hepatoblastoma","Bisulfite pyrosequencing analysis also confirmed CSF3R was significantly hypermethylated in cisplatin-resistant patients.  Among.  cisplatin-sensitive patients, recurrence curves showed that the CSF3R high methylation patients had significantly higher recurrence than CSF3R low methylation patients","https://www.ncbi.nlm.nih.gov/pubmed/31894653","High_Unfavourable",NA,"DB00515","135804801","ENSG00000119535","EFO_1000292","CSF3R DNA HYPERMETHYLATION NA","pass"
"26","SORAFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","miR-744,PAX2","RNA,expression",NA,"Patients",31553714,"Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2","downregulated miR-744 promotes HepG2 cell proliferation and inhibits the chemosensitivity of HepG2 cells to sorafenib. PAX2 was identified as the functional target of miR-744. Interestingly, miR-744 is decreased in exosomes derived from sorafenib-resistant HepG2 cells. Serum exosomal miR-744 might act as a biomarker of HCC, and exosomal miR-744 might offer an innovative strategy for HCC treatment.","https://www.ncbi.nlm.nih.gov/pubmed/31553714","High_Unfavourable,High_Unfavourable",NA,"DB00398","406563","NA, ENSG00000075891","EFO_0000182","failed","failed biomarker,failed term"
"27","NA","NA","INTRAHEPATIC CHOLANGIOCARCINOMA","MFAP5","expression",NA,"mouse",31775892,"MFAP5 Facilitates the Aggressiveness of Intrahepatic Cholangiocarcinoma by Activating the Notch1 Signaling Pathway"," We identified MFAP5 as a biomarker for the diagnosis and prognosis of ICC. Upregulated MFAP5 is a common feature in aggressive ICC patients' tissues. Importantly, MFAP5 level in the serum of ICC patients and healthy individuals showed significant differential expression profiles.","https://www.ncbi.nlm.nih.gov/pubmed/31775892","High_Unfavourable",NA,"NA","56956252","ENSG00000197614","EFO_1001961","MFAP5 EXPRESSION NA","pass"
"28","SORAFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","IFN-γ","expression",NA,"Patients",31391334,"Augmentation of IFN-γ+ CD8+ T Cell Responses Correlates With Survival of HCC Patients on Sorafenib Therapy","elevated levels of CD8+Ki67+ T cells producing IFN-γ were associated with improved progression-free survival and overall survival .CD8+Ki67+ T cells producing IFN-γ are a key biomarker of response to sorafenib therapy resulting in survival benefit. ","https://www.ncbi.nlm.nih.gov/pubmed/31391334","High_favourable",NA,"DB00398","406563","NA","EFO_0000182","IFN-Γ EXPRESSION NA","failed biomarker"
"29","OXALIPLATIN","NA","HEPATOCELLULAR CARCINOMA","CCN2,ID1","expression,expression",NA,"NA",31250351,"CCN2-MAPK-Id-1 Loop Feedback Amplification Is Involved in Maintaining Stemness in Oxaliplatin-Resistant Hepatocellular Carcinoma","Upregulation of CCN2 and Id-1 was independently associated with shorter survival and increased recurrence in HCC patients, and significantly enhanced oxaliplatin resistance and promoted lung metastasis in vivo, whereas knock-down of their expression significantly reversed the chemo-resistance and inhibited HCC cell stemness. ","https://www.ncbi.nlm.nih.gov/pubmed/31250351","High_Unfavourable,High_Unfavourable",NA,"DB00526","71301229","ENSG00000118523, ENSG00000125968","EFO_0000182","failed","failed term"
"30","SORAFENIB, BEZ‑235","Multikinase,AKT","LIVER CANCER","FoxM1,AP1,AKT","expression,expression,expression",NA,"celline",31233189,"Activation of AKT/AP1/FoxM1 Signaling Confers Sorafenib Resistance to Liver Cancer Cells","forkhead box M1 (FoxM1) was significantly overexpressed in sorafenib‑resistant cells, at the mRNA and protein levels. Knockdown of FoxM1 rendered drug‑tolerant cells sensitive to sorafenib. there is an activator protein‑1 (AP1) binding site in the promoter of FoxM1.Inhibition of AKT using BEZ‑235 markedly suppressed the upregulation of c‑jun and FoxM1, and increased the sensitivity of drug‑resistant cells to sorafenib in vitro and in vivo.","https://www.ncbi.nlm.nih.gov/pubmed/31233189","High_Unfavourable",NA,"DB00398,NA","406563, 11977753","ENSG00000111206, ENSG00000177606, ENSG00000166971","MONDO_0002691","failed","failed term"
"31","SORAFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","KPNA3","expression",NA,"PDX,Patients",31417635,"KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition","Overexpression of KPNA3 in HCC cells enhanced tumor cell growth and invasiveness. novel KPNA3-AKT-ERK-TWIST signaling cascade that promotes EMT and mediates sorafenib resistance in HCC. retrospective analysis revealed that HCC patients with low KPNA3 expression had remarkably longer survival after sorafenib treatment.","https://www.ncbi.nlm.nih.gov/pubmed/31417635","High_Unfavourable",NA,"DB00398","406563","ENSG00000102753","EFO_0000182","KPNA3 EXPRESSION NA","pass"
"32","SORAFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","BRMS1","expression",NA,"celline",31233204,"Synergistic Antitumor Effect of BRMS1 and Sorafenib via Inhibition of the PI3K/AKT/mTOR/ERK Signaling Pathway","overexpression of BRMS1 potentiated the effect of sorafenib via PI3K/AKT/mTOR/ERK signaling, while knockdown of BRMS1 expression attenuated this effect.","https://www.ncbi.nlm.nih.gov/pubmed/31233204","High_favourable",NA,"DB00398","406563","ENSG00000174744","EFO_0000182","BRMS1 EXPRESSION NA","pass"
"33","SORAFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","TARBP2","expression",NA,"NA",30657254,"TARBP2-mediated Destabilization of Nanog Overcomes Sorafenib Resistance in Hepatocellular Carcinoma","TARBP2 is significantly downregulated in sorafenib-resistant HCC cells.","https://www.ncbi.nlm.nih.gov/pubmed/30657254","Low_Unfavourable",NA,"DB00398","406563","ENSG00000139546","EFO_0000182","TARBP2 EXPRESSION NA","pass"
"34","NA","PARP1","HEPATOCELLULAR CARCINOMA","EGFR,MET","expression,expression",NA,"NA",30573522,"EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma","Inhibition of both EGFR and MET sensitized HCC cells to PARPi, and both EGFR and MET are known to be overexpressed in HCC. Regulation of PARP by the c-MET and EGFR heterodimer suggests a potentially effective combination therapy to sensitize HCC to PARPi.","https://www.ncbi.nlm.nih.gov/pubmed/30573522","High_Unfavourable",NA,"NA","56956252","ENSG00000146648, ENSG00000105976","EFO_0000182","failed","failed term"
"35","SOREFENIB, REGORAFENIB","Multikinase , NA","HEPATOCELLULAR CARCINOMA","albumin-bilirubin score","serum-level",NA,"Patients",30380075,"Using ALBI Score at the Start of Sorafenib Treatment to Predict Regorafenib Treatment Candidates in Patients With Hepatocellular Carcinoma","The albumin-bilirubin score is a good biomarker for hepatic reserve function.albumin-bilirubin score at the start of sorafenib therapy is a useful marker for identifying candidate patients for starting regorafenib therapy.","https://www.ncbi.nlm.nih.gov/pubmed/30380075",NA,NA,"NA,DB08896","NA, 24768591","NA","EFO_0000182","ALBUMIN-BILIRUBIN SCORE SERUM-LEVEL NA","failed drug,failed biomarker"
"36","ADRIAMYCIN","NA","HEPATOCELLULAR CARCINOMA","YAP1","expression",NA,"NA",30111512,"miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression.","YAP1-mediated chemoresistant phenotype was closely related to increased expression of stemness markers and ATP-binding cassette transporters. HCC patients with poor response to transarterial chemoembolization (TACE) treatment had higher protein level of YAP1 than that in the responsive patients.","https://www.ncbi.nlm.nih.gov/pubmed/30111512","High_Unfavourable",NA,"NA","443939","ENSG00000137693","EFO_0000182","YAP1 EXPRESSION NA","pass"
"37","NA","NA","HBV-HEPATOCELLULAR CARCINOMA","ALT, AST, NLR, AFP","serum-level,serum-level,serum-level,serum-level",NA,"Patients",32150664,"Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma.","The diagnostic performance of AFP combined with ALT, AST, and NLR for HBV-HCC was superior to single biomarker or any other combinations among these patients, and its diagnostic equation can be used as useful tool for differentiation of HBV-HCC from Chronic hepatitis B.","https://www.ncbi.nlm.nih.gov/pubmed/32150664",NA,NA,"NA","56956252","NA, ENSG00000119899, ENSG00000179583, ENSG00000081051","EFO_0000707","failed","failed biomarker,failed term"
"38","NA","NA","LIVER CANCER","ORM2","expression",NA,"Patients",32148378,"Downregulation of orosomucoid 2 acts as a prognostic factor associated with cancer-promoting pathways in liver cancer.","ORM1 and ORM2 were highly expressed specifically in liver tissues, whereas ORM1 and ORM2 were downregulated in liver tumor tissues. ORM2 is a better prognostic factor for liver cancer. Furthermore, ORM2 is closely associated with cancer-promoting pathways.","https://www.ncbi.nlm.nih.gov/pubmed/32148378","Low_Unfavourable",NA,"NA","56956252","ENSG00000228278","MONDO_0002691","ORM2 EXPRESSION NA","pass"
"39","NA","NA","HEPATOCELLULAR CARCINOMA","YTHDF1, YTHDF2, METTL3, KIAA1429","expression,expression,expression,expression",NA,"Patients",32111180,"Multiple m6A RNA methylation modulators promote the malignant progression of hepatocellular carcinoma and affect its clinical prognosis.","Four m6A RNA methylation modulators (YTHDF1, YTHDF2, METTL3, and KIAA1429) affecting OS in the TCGA and ICGC analyses were selected to construct a risk signature, which was significantly associated with WHO stage and was also an independent prognostic marker of OS.","https://www.ncbi.nlm.nih.gov/pubmed/32111180",NA,NA,"NA","56956252","ENSG00000149658, ENSG00000198492, ENSG00000165819, ENSG00000164944","EFO_0000182","failed","failed term"
"40","NA","NA","HEPATOCELLULAR CARCINOMA","circPCNX ,PCNX","RNA,RNA",NA,"Patients",32099459,"circPCNX and Pecanex Promote Hepatocellular Carcinoma Cell Viability by Inhibiting miR-506.","study revealed the function of circPCNX and Pecanex in promoting HCC progression and acting as biomarkers in the clinical estimate and treatment of HCC. we observed that circPCNX and Pecanex were significantly upregulated in tumor tissues of patients with HCC and correlated with clinicopathological variables or prognosis of HCC patients","https://www.ncbi.nlm.nih.gov/pubmed/32099459","High_Unfavourable,High_Unfavourable",NA,"NA","56956252","NA, ENSG00000100731","EFO_0000182","failed","failed biomarker,failed term"
"41","NA","NA","HEPATOCELLULAR CARCINOMA","BZRAP1-AS1","RNA",NA,"cellines,tissues",31847842,"Long non-coding RNA BZRAP1-AS1 silencing suppresses tumor angiogenesis in hepatocellular carcinoma by mediating THBS1 methylation.","BZRAP1-AS1 was identified as a highly expressed lncRNA in HCC tissues and cells. BZRAP1-AS1 may be a promising marker for the treatment of HCC.","https://www.ncbi.nlm.nih.gov/pubmed/31847842","High_Unfavourable",NA,"NA","56956252","NA","EFO_0000182","BZRAP1-AS1 RNA NA","failed biomarker"
"42","NA","NA","LIVER CANCER","ANXA2, ANXA5, ANXA7,ANXA10","expression,expression,expression,expression",NA,"NA",31807177,"Expression levels and prognostic values of annexins in liver cancer.","present study suggested that  that ANXA2, A5, A7 and A10 may be potential prognostic biomarkers of liver cancer. High expression levels of ANXA2 and A5 were significantly associated with poor overall survival (OS) rate whereas ANXA7 and A10 were associated with increased OS.","https://www.ncbi.nlm.nih.gov/pubmed/31807177","High_Unfavourable,High_Unfavourable,High_favourable,High_favourable",NA,"NA","56956252","ENSG00000182718, ENSG00000164111, ENSG00000138279, ENSG00000109511","MONDO_0002691","failed","failed term"
"43","NA","NA","HEPATOCELLULAR CARCINOMA","FGF19","serum-level",NA,"Patients",31718608,"Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma.","FGF19 showed higher sensitivity for the detection of small HCC (solitary cancer with diameter < 20 mm) than those of existing markers.","https://www.ncbi.nlm.nih.gov/pubmed/31718608","High_Unfavourable",NA,"NA","56956252","ENSG00000162344","EFO_0000182","FGF19 SERUM-LEVEL NA","pass"
"44","NA","NA","INTRAHEPATIC CHOLANGIOCARCINOMA","CA19-9 , HIF-1,HDAC","serum-level,expression,expression",NA,"Patients",31704828,"Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1α for Intrahepatic Cholangiocarcinoma.","High serum CA19-9 level is a poor prognostic factor for overall survival in IHCC and correlates with HIF-1α and HDAC1 expression.","https://www.ncbi.nlm.nih.gov/pubmed/31704828","High_Unfavourable",NA,"NA","56956252","NA, ENSG00000168209, ENSG00000068024","EFO_1001961","failed","failed biomarker,failed term"
"45","NA","NA","HEPATOCELLULAR CARCINOMA","MAGEC2","expression",NA,"PDX,Patients",31576142,"MAGEC2 Correlates With Unfavorable Prognosis And Promotes Tumor Development In HCC Via Epithelial-Mesenchymal Transition.","remarkably higher level of MAGEC2 expression in HCC tissues than in noncancerous tissues, and MAGEC2 expression could be used as an independent prognostic factor for overall survival in HCC","https://www.ncbi.nlm.nih.gov/pubmed/31576142","High_Unfavourable,High_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000046774","EFO_0000182","MAGEC2 EXPRESSION NA","pass"
"46","GEMCITABINE","NA","CHOLANGIOCARCINOMA","OCT_4","expression",NA,"celline",31554372,"The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines.","CCA cells can adapt to survive in acidic environment after which chemoresistance has been developed. Oct4 may be a key transcriptional regulator which mediates chemoresistance in response to acidic extracellular pH.","https://www.ncbi.nlm.nih.gov/pubmed/31554372","High_Unfavourable",NA,"DB00441","60750","ENSG00000204531","EFO_0005221","OCT_4 EXPRESSION NA","pass"
"47","NA","NA","HEPATOCELLULAR CARCINOMA","AFP, CD133, EPCAM,  KRT19 , ALB, G6PC, CYP3A4, HNF4A","expression,expression,expression,expression,expression,expression,expression,expression,",NA,"NA",31462277,"Development of an oncogenic dedifferentiation SOX signature with prognostic significance in hepatocellular carcinoma."," Liver cancer dedifferentiation markers (AFP, CD133, EPCAM, and KRT19) were found to be progressively increased while hepatocyte terminal differentiation markers (ALB, G6PC, CYP3A4, and HNF4A) were progressively decreased from HCC patients with low SOX signature.An oncogenic dedifferentiation SOX signature presents a great potential in predicting prognostic significance in HCC, and might provide novel biomarkers for precision oncology further in the clinic. scores to patients with high SOX signature scores.","https://www.ncbi.nlm.nih.gov/pubmed/31462277","need to check full text for SOX signature",NA,"NA","56956252","ENSG00000081051, ENSG00000007062, ENSG00000119888, ENSG00000171345, ENSG00000163631, ENSG00000131482, ENSG00000160868, ENSG00000101076","EFO_0000182","failed","failed term"
"48","RIBOCICLIB","CDK4,CDK6","HEPATOCELLULAR CARCINOMA","RB,p16-encoding CDKN2A","expression,expression",NA,"NA",31250364,"Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.","Our results warrant further investigation of Rb and p16 expression as markers of HCC sensitivity to ribociclib. mRNA analysis of primary human HCC specimens showed that CDK4 expression was correlated with patient survival and that the expression of Rb and the p16-encoding CDKN2A gene were inversely correlated.","https://www.ncbi.nlm.nih.gov/pubmed/31250364",NA,NA,"DB11730","44631912","ENSG00000139687, NA","EFO_0000182","failed","failed term"
"49","NA","NA","HEPATOCELLULAR CARCINOMA","CRIPTO1","expression",NA,"celllines,patients",31136302,"Beneficial effects of Cripto-1 for transarterial chemoembolization in hepatocellular carcinoma.","Cripto-1 may be a potential prognostic factor in predicting outcome of HCC patients with TACE therapy, and combined with Cripto-1 and tumor features may be helpful to stratify patients with respect to prognosis and response to adjuvant TACE. in high Cripto-1 expression patients, those with adjuvant TACE had favorable TTR and OS times. On contrary, adjuvant TACE may promote tumor recurrence but had no influence on OS time in patients with low Cripto-1 expression.","https://www.ncbi.nlm.nih.gov/pubmed/31136302","High_Unfavourable",NA,"NA","56956252","NA","EFO_0000182","CRIPTO1 EXPRESSION NA","failed biomarker"
"50","SOREFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","SLC46A3","expression",NA,"cells,tissues,patients",309811107,"Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.","increased expression of SLC46A3 could favor a better clinical prognosis for patients with HCC, ameliorate sorafenib resistance, and improve drug response. SLC46A3 might serve as a potential prognostic biomarker and therapeutic target in HCC.","https://www.ncbi.nlm.nih.gov/pubmed/30981107","High_favourable",NA,"NA","NA","ENSG00000139508","EFO_0000182","SLC46A3 EXPRESSION NA","failed drug"
"51","NA","NA","HEPATOCELLULAR CARCINOMA","AKR1B10","expression",NA,"NA",30959792,"Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma.","AKR1B10 has emerged as a potential biomarker for the diagnosis and prognosis of HCC","https://www.ncbi.nlm.nih.gov/pubmed/30959792","High_unfavourable",NA,"NA","56956252","ENSG00000198074","EFO_0000182","AKR1B10 EXPRESSION NA","pass"
"52","NA","NA","HEPATOCELLULAR CARCINOMA","LncRNA-MINCR, CDK2 mRNA","RNA,RNA",NA,"tissues",30947664,"Expression and Significance of LncRNA-MINCR and CDK2 mRNA in Primary Hepatocellular Carcinoma.","High expression of LncRNA-MINCR and CDK2 mRNA indicates poor prognosis in patients with hepatocellular carcinoma","https://www.ncbi.nlm.nih.gov/pubmed/30947664","High_Unfavourable,High_Unfavourable",NA,"NA","56956252","NA, NA","EFO_0000182","failed","failed biomarker,failed term"
"53","NA","NA","HEPATOCELLULAR CARCINOMA","UBE2C","expression",NA,"Patients",30914455,"UBE2C functions as a potential oncogene by enhancing cell proliferation, migration, invasion, and drug resistance in hepatocellular carcinoma cells.","Elevated UBE2C mRNA levels in HCC indicated worsened survival probabilities. UBE2C emerges as a marker for prognosis in HCC, and blocking UBE2C may be a novel strategy for HCC therapies.","https://www.ncbi.nlm.nih.gov/pubmed/30914455","High_Unfavourable",NA,"NA","56956252","ENSG00000175063","EFO_0000182","UBE2C EXPRESSION NA","pass"
"54","NA","NA","HEPATOCELLULAR CARCINOMA","CD8,CD25,FOXP3","expression,expression,expression","positive,positive,positive","Patients",30904437,"Increased frequency and FOXP3 expression of human CD8+CD25High+ T lymphocytes and its relation to CD4 regulatory T cells in patients with hepatocellular carcinoma.","Our results revealed that the percentage of peripheral CD8+CD25High+FOXP3+ T cells in HCC patients was significantly higher than controls (P = 0.005).  CD8+CD25High+FOXP3+ T cells similar to conventional Tregs might be used as biomarkers of HCC progression.","https://www.ncbi.nlm.nih.gov/pubmed/30904437","positive unfavourable ,positive unfavourable,positive unfavourable",NA,"NA","56956252","ENSG00000153563, ENSG00000134460, ENSG00000049768","EFO_0000182","failed","failed term"
"55","NA","NA","CHOLANGIOCARCINOMA","CES2","expression",NA,"Patients",30867471,"Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma.","CES2 expression may serve as a predictive marker in patients treated with prodrugs converted by CES2.  reduced CES2 expression is associated with poor outcome and low CD8+ T cell infiltration in CCA patients.","https://www.ncbi.nlm.nih.gov/pubmed/30867471",NA,NA,"NA","56956252","ENSG00000172831","EFO_0005221","CES2 EXPRESSION NA","pass"
"56","NA","NA","LIVER CANCER","DYRK2","expression",NA,"Patients",30851422,"Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer.","DYRK2 expression could be a promising predictive marker of the prognosis in liver cancer. overexpression of DYRK2 resulted in inhibition of cell proliferation and tumor growth, and induction of apoptosis both in vitro and in vivo. Furthermore, we found that liver cancer patients with low DYRK2 expression had a significantly shorter overall survival","https://www.ncbi.nlm.nih.gov/pubmed/30851422",NA,NA,"NA","56956252","ENSG00000127334","MONDO_0002691","DYRK2 EXPRESSION NA","pass"
"57","NA","NA","HEPATOCELLULAR CARCINOMA","PTK2","expression",NA,"tissues",30849480,"PTK2 promotes cancer stem cell traits in hepatocellular carcinoma by activating Wnt/β-catenin signaling.","PTK2 may be a novel prognostic biomarker for HCC recurrence, and a therapeutic target for HCC treatment.  PTK2 apparently acts as an oncogene by increasing CSC traits and tumorigenicity in HCC.","https://www.ncbi.nlm.nih.gov/pubmed/30849480","High_Unfavourable",NA,"NA","56956252","ENSG00000169398","EFO_0000182","PTK2 EXPRESSION NA","pass"
"58","NA","NA","LIVER CANCER","B3GAT3","expression",NA,"celline",30847403,"High Expression B3GAT3 Is Related with Poor Prognosis of Liver Cancer.","overexpressed B3GAT3 promotes the process of tumor EMT, which is an independent prognostic marker to predict the prognosis of liver cancer and might be a potential new target for liver cancer therapy.","https://www.ncbi.nlm.nih.gov/pubmed/30847403","High_Unfavourable",NA,"NA","56956252","ENSG00000149541","MONDO_0002691","B3GAT3 EXPRESSION NA","pass"
"59","NA","NA","HEPATOCELLULAR CARCINOMA","FBXO22","expression",NA,"cellines,tissues",30808376,"FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.","both in vitro and in vivo experiments showed that knocking down FBXO22 expression could inhibit cell proliferation, while overexpression of FBXO22 promoted tumor formation","https://www.ncbi.nlm.nih.gov/pubmed/30808376","High_Unfavourable",NA,"NA","56956252","ENSG00000167196","EFO_0000182","FBXO22 EXPRESSION NA","pass"
"60","REGORAFENIB","NA","HEPATOCELLULAR CARCINOMA","miR-30A, miR-122, miR-125B, miR-200A, miR-374B, miR-15B, miR-107, miR-320, miR-645,CTNNB1,VEGFA","expression,expression,expression,expression,expression,expression,expression,expression,expression,mutation,amplification",NA,"Patients",30738047,"Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.","We identified 9 plasma miRNAs (miR-30A, miR-122, miR-125B, miR-200A, miR-374B, miR-15B, miR-107, miR-320, and miR-645) whose levels significantly associated with overall survival time with regorafenib (adjusted P ≤ .05). Functional analyses of these miRNAs indicated that their expression level associated with increased overall survival of patients with tumors of the Hoshida S3 subtype. Mutations in CTNNB1 were detected in 3 of 10 progressors and VEGFA amplification in 1 of 7 responders.","https://www.ncbi.nlm.nih.gov/pubmed/30738047","High_Favourable,High_Favourable,High_Favourable,High_Favourable,High_Favourable,High_Favourable,High_Favourable,High_Favourable,High_Favourable, Unfavourable, Favourable",NA,"DB08896","24768591","NA, ENSG00000284440, NA, NA, NA, NA, NA, NA, NA, ENSG00000168036, ENSG00000112715","EFO_0000182","failed","failed biomarker,failed term"
"61","NA","NA","HEPATOCELLULAR CARCINOMA","survivin , endoglin","protein expression,protein expression",NA,"Patients",30730204,"Elevated Expressions of Survivin and Endoglin in Patients with Hepatic Carcinoma.","Elevated expressions of survivin and endoglin are associated with histological grade, tumor size, and TNM stage in patients with hepatic carcinoma, indicating that survivin and endoglin might be involved in the pathogenesis of hepatic carcinoma and therapeutic targeting them might be a novel approach for the treatment of hepatic carcinoma.","https://www.ncbi.nlm.nih.gov/pubmed/30730204","High_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000089685, ENSG00000106991","EFO_0000182","failed","failed term"
"62","NA","NA","HEPATOCELLULAR CARCINOMA","CDH1","mRNA expression/methylation",NA,"Patients",30697077,"Clinicopathological and prognostic significance of CDH1 hypermethylation in hepatocellular carcinoma: a meta-analysis.","CDH1 promoter hypermethylation is a risk factor and promising biomarker for HCC carcinogenesis and diagnosis, as well as a predictor of poor prognosis. High CDH1 mRNA expression was significantly correlated to better overall survival. CDH1 promoter in HCC was more frequently hypermethylated","https://www.ncbi.nlm.nih.gov/pubmed/30697077","High_favourable/High_Unfavourable",NA,"NA","56956252","ENSG00000039068","EFO_0000182","CDH1 MRNA EXPRESSION/METHYLATION NA","pass"
"63","SOREFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","NRAS,KRAS","expression,expression",NA,"celline",30685691,"Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.","KRAS upregulation served as a functional compensatory mechanism in the absence of NRAS, which was overcome by combined inhibition of NRAS and KRAS in HCC cells. NRAS expression was elevated in sorafenib-resistant compared to nonresistant HCC cells, and NRAS knockdown enhanced sorafenib efficacy in resistant cells. NRAS appears to be a prognostic marker in HCC and contributes to sorafenib resistance. NRAS inhibition in HCC should be combined with KRAS inhibition to prevent KRAS-mediated rescue effects.","https://www.ncbi.nlm.nih.gov/pubmed/30685691","High_Unfavourable,High_Unfavourable",NA,"NA","NA","ENSG00000213281, ENSG00000133703","EFO_0000182","failed","failed drug,failed term"
"64","NA","NA","HEPATOCELLULAR CARCINOMA","Cytokeratin19 was associated , sal-like protein 4","expression,protein expression",NA,"Patients",30588199,"The Prognostic Value of Cytokeratin and Sal-Like Protein 4 Expression in Hepatocellular Carcinoma and Intra-Hepatic Cholangiocarcinoma in Taiwan.","The expression of cytokeratin19 was associated with sal-like protein 4 expression, as well as poor overall and disease-free survival in hepatocellular carcinoma patients","https://www.ncbi.nlm.nih.gov/pubmed/30588199","High_Unfavourable,High_Unfavourable",NA,"NA","56956252","NA, ENSG00000101115","EFO_0000182","failed","failed biomarker,failed term"
"65","REGORAFENIB","NA","HEPATOCELLULAR CARCINOMA","Pin1","expression",NA,"celline",30583078,"Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway.","generated Regorafenib-resistant HCC cells and found that they exhibited enhanced tumor invasion and metastasis in vitro and in vivo, and elevated Pin1 levels.  Depletion or overexpression of Pin1 correspondingly inhibited or promoted HCC cell migration and invasion, with altered expression of EMT-related molecules","https://www.ncbi.nlm.nih.gov/pubmed/30583078","High_Unfavourable",NA,"DB08896","24768591","ENSG00000127445","EFO_0000182","PIN1 EXPRESSION NA","pass"
"66","NA","NA","HEPATOCELLULAR CARCINOMA","FBP1","expression",NA,"celline",30429463,"Restoration of FBP1 suppressed Snail-induced epithelial to mesenchymal transition in hepatocellular carcinoma.","a vital role for FBP1 in Snail-induced EMT and prognostic prediction in HCC. we demonstrated that FBP1 was significantly inhibited during Snail-induced epithelial to mesenchymal transition (EMT) and tissues in HCC.Low FBP1 expression was significantly correlated with higher AFP level","https://www.ncbi.nlm.nih.gov/pubmed/30429463","Low_Unfavourable",NA,"NA","56956252","ENSG00000165140","EFO_0000182","FBP1 EXPRESSION NA","pass"
"67","GEMCITABINE","NA","INTRAHEPATIC CHOLANGIOCARCINOMA","SOX9","expression",NA,"celline",30420613,"SOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance.","iCCA patients with high SOX9 expression had shorter survival time than those with low SOX9. When SOX9 was knocked down, gemcitabine-induced apoptosis was markedly increased. SOX9 is a biomarker to select iCCA patients eligible for efficient.Silencing SOX9 significantly inhibited gemcitabine-induced phosphorylation of checkpoint kinase 1, a key cell cycle checkpoint protein that coordinates the DNA damage response and inhibited the expression of multidrug resistance genes. chemotherapy.","https://www.ncbi.nlm.nih.gov/pubmed/30420613","High_Unfavourable",NA,"DB00441","60750","ENSG00000125398","EFO_1001961","SOX9 EXPRESSION NA","pass"
"68","NA","NA","INTRAHEPATIC CHOLANGIOCARCINOMA","BAP-1,PBRM-1,S100P","expression,expression,expression",NA,"Patients",30377796,"Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma.","In ICC, a retained expression of BAP-1 and PBRM-1, and an overexpression of S100P are related to a poor prognosis. A strong retained expression of BAP-1 and PBRM-1 was associated with a reduced overall. An overexpression of S100P was related to a reduced overall survival","https://www.ncbi.nlm.nih.gov/pubmed/30377796",",,High_Unfavourable",NA,"NA","56956252","ENSG00000121481, ENSG00000163939, ENSG00000163993","EFO_1001961","failed","failed term"
"69","SORAFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","H1F-1A,H1F-2A","expression,expression",NA,"Patients",30315182,"Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors.","Clinical data have demonstrated that overexpressed HIF-1α and HIF-2α in HCC patients are reliable markers of a poor prognosis. . there is a marked correlation between the hypoxic microenvironment and sorafenib resistance, suggesting that targeting HIFs is a promising way to increase the efficiency of treatment.","https://www.ncbi.nlm.nih.gov/pubmed/30315182","High_Unfavourable,High_Unfavourable",NA,"DB00398","406563","NA, NA","EFO_0000182","failed","failed biomarker,failed term"
"70","NA","NA","HEPATOCELLULAR CARCINOMA","MCT4,GLUT1","expression,expression",NA,"Patients",30306706,"Aberrant MCT4 and GLUT1 expression is correlated with early recurrence and poor prognosis of hepatocellular carcinoma after hepatectomy.","sing the expression of MCT4 and GLUT1 and their metabolic parameters to determine the metabolic status of tumors is promising for predicting the prognosis of patients with HCC. MCT4 and GLUT1 expression levels were significantly higher in tumor tissues than in adjacent nontumor tissues, and they were positively correlated with tumor size. Survival analysis showed that patients with high expression levels of MCT4 or GLUT1 had a poor OS and TTR.","https://www.ncbi.nlm.nih.gov/pubmed/30306706","High_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000141526, ENSG00000117394","EFO_0000182","failed","failed term"
"71","NA","NA","INTRAHEPATIC CHOLANGIOCARCINOMA","CD90","expression",NA,"celline",30196535,"CD90 expression in human intrahepatic cholangiocarcinoma is associated with lymph node metastasis and poor prognosis.","CD90+ cells demonstrate high metastatic potential owing to Wnt/β-catenin signaling activation and are associated with poor prognosis in ICC.CD90 expression was significantly associated with lymph node metastasis and was revealed to be an independent prognostic factor.","https://www.ncbi.nlm.nih.gov/pubmed/30196535","Positive unfavourable",NA,"NA","56956252","ENSG00000154096","EFO_1001961","CD90 EXPRESSION NA","pass"
"72","NA","P38","INTRAHEPATIC CHOLANGIOCARCINOMA","S100A11","expression",NA,"celline",30182496,"S100A11 promotes cell proliferation via P38/MAPK signaling pathway in intrahepatic cholangiocarcinoma.","High expression of S100A11 was closely correlated with lymph node metastasis (LNM) and TNM stage and was an independent risk factor for patients' overall survival (OS) and recurrence-free survival (RFS). S100A11-induced proliferation was abolished after treatment with P38 inhibitor. Our findings suggest S100A11/P38/MAPK signaling pathway may be a potential therapeutic target for ICC patients.","https://www.ncbi.nlm.nih.gov/pubmed/30182496","High_Unfavourable",NA,"NA","56956252","ENSG00000163191","EFO_1001961","S100A11 EXPRESSION NA","pass"
"73","NA","NA","HEPATOCELLULAR CARCINOMA","HUS1","expression",NA,"tissues",30182378,"HUS1 checkpoint clamp component (HUS1) is a potential tumor suppressor in primary hepatocellular carcinoma.","HUS1 is a potential tumor suppressor that might produce an antitumor effect in human HCC. Furthermore, HUS1 may serve as a prognostic indicator and could be used for therapeutic application in HCC patients. he expression of HUS1 was significantly decreased in HCC cell lines and tissues, and low HUS1 expression was associated with poor prognosis of HCC patients.","https://www.ncbi.nlm.nih.gov/pubmed/30182378","Low_Unfavourable",NA,"NA","56956252","ENSG00000136273","EFO_0000182","HUS1 EXPRESSION NA","pass"
"74","NA","NA","HEPATOCELLULAR CARCINOMA","miR22","expression",NA,"Patients",32088997,"The expression level and diagnostic value of microRNA-22 in HCC patients.","miR-22 expression was down-regulated in HCC patients. Serum miR-22 might be a novel diagnostic marker in HCC.","https://www.ncbi.nlm.nih.gov/pubmed/32088997","Low_Unfavourable",NA,"NA","56956252","ENSG00000283824","EFO_0000182","MIR22 EXPRESSION NA","pass"
"75","NA","NA","HEPATOCELLULAR CARCINOMA","GTSE1, CDC20, PCNA, MCM6","gene expression ,gene expression ,gene expression ,gene expression",NA,"celline",32082966,"GTSE1, CDC20, PCNA, and MCM6 Synergistically Affect Regulations in Cell Cycle and Indicate Poor Prognosis in Liver Cancer.","Genes like GTSE1, CDC20, PCNA, and MCM6 may be promising prognostic molecular biomarkers in liver cancer. GTSE1, together with CDC20, PCNA, and MCM6, may synergistically promote adverse prognosis in HCC by activating cell cycle.","https://www.ncbi.nlm.nih.gov/pubmed/32082966","High_Unfavourable,High_Unfavourable,High_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000075218, ENSG00000117399, ENSG00000132646, ENSG00000076003","EFO_0000182","failed","failed term"
"76","NA","NA","PRIMARY HEPATIC CANCER"," CTSB rs12898","expression",NA,"Patients",31934146,"A single nucleotide polymorphism CTSB rs12898 is associated with primary hepatic cancer in a Chinese population.","Results suggest that CTSB rs12898G > A may play a role in the pathogenesis of PHC, and may be a marker for susceptibility to PHC. CTSB rs12898 was associated with a significantly increased risk of PHC under a dominant model","https://www.ncbi.nlm.nih.gov/pubmed/31934146","High_Unfavourable , chinese population",NA,"NA","56956252","NA","EFO_0000311","CTSB RS12898 EXPRESSION NA","failed biomarker"
"77","NA","NA","INTRAHEPATIC CHOLANGIOCARCINOMA","miR-212-3p,MUC13","RNA,expression",NA,"celline",31837357,"MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.","mucin 13 plays a critical role in intrahepatic cholangiocarcinoma. Mucin 13 could have therapeutic value both as a prognostic marker and as a treatment target. loss-of-function and gain-of-function experiments suggested that knockdown of MUC13. aberrant hypermethylation-induced downregulation of miR-212-3p results in overexpression of MUC13 in iCCA attenuated, while overexpression of MUC13 enhanced, the proliferation, motility, and invasiveness of iCCA cells in vitro and in vivo.","https://www.ncbi.nlm.nih.gov/pubmed/31837357","Low_Unfavourable,High_Unfavourable",NA,"NA","56956252","NA, ENSG00000173702","EFO_1001961","failed","failed biomarker,failed term"
"78","NA","NA","HEPATOCELLULAR CARCINOMA","GPC3,GS","protein expression,protein expression",NA,"Tissues",31832976,"Improving pathological early diagnosis and differential biomarker value for hepatocellular carcinoma via RNAscope technology.","cases that were negative for GPC3 by RNAscope were also negative for this protein by IHC.
RNAscope for GPC3 and GS panel was highly specific and sensitive for the pathological identification of dysplastic nodules, early stages of HCCs, and would differentiate them from HCCs and metastatic tumors compared with IHC.","https://www.ncbi.nlm.nih.gov/pubmed/31832976",NA,NA,"NA","56956252","ENSG00000147257, ENSG00000169840","EFO_0000182","failed","failed term"
"79","NA","NA","HEPATOCELLULAR CARCINOMA","HMGA2","expression",NA,"Patients",31823639,"Elevated high mobility group A2 expression in liver cancer predicts poor patient survival.","HMGA2 independently predicts poor prognosis in liver cancer and serves as a molecular marker to determine disease prognosis.  HMGA2 was overexpressed in liver cancer","https://www.ncbi.nlm.nih.gov/pubmed/31823639","High_Unfavourable",NA,"NA","56956252","ENSG00000149948","EFO_0000182","HMGA2 EXPRESSION NA","pass"
"80","NA","NA","HEPATOCELLULAR CARCINOMA","miR-130b ,miR-21","RNA,RNA",NA,"Patients",31660696,"Circulating miR-130b- and miR-21-based diagnostic markers and therapeutic targets for hepatocellular carcinoma.","The circulating miR-130b and miR-21 can be used as potential tumor biomarkers to diagnose liver cancer, and the combined detection of serum miR-130b and miR-21 is superior to the diagnosis of HCC. circulating miR-130b and miR-21 were all upregulated in patients with HCC.","https://www.ncbi.nlm.nih.gov/pubmed/31660696","High_Unfavourable,High_Unfavourable",NA,"NA","56956252","NA, ENSG00000284190","EFO_0000182","failed","failed biomarker,failed term"
"81","NA","NA","HEPATOCELLULAR CARCINOMA","Midkine,thioredoxin,1-methyladenosine ,1-methylguanosine","protein expression, protein expression,protein expression,protein expression",NA,"Patients",31648804,"A combination of α-fetoprotein, midkine, thioredoxin and a metabolite for predicting hepatocellular carcinoma.","Four markers were measured: Midkine and thioredoxin using ELISA, 1-methyladenosine and 1-methylguanosine using a gas chromatography-mass spectrometry (GC-MS). The results were compared with alpha-fetoprotein (AFP). This model may enhance early-stage HCC detection and help to overcome insufficient sensitivity of AFP.","https://www.ncbi.nlm.nih.gov/pubmed/31648804",NA,NA,"NA","56956252","ENSG00000110492, ENSG00000265972, NA, NA","EFO_0000182","failed","failed term"
"82","NA","NA","LIVER CANCER","CDKN2B-AS1","expression",NA,"tissues",31646789,"Overexpressed lncRNA CDKN2B-AS1 is an independent prognostic factor for liver cancer and promotes its proliferation.","The expression of CDKN2B-AS1 in liver cancer was significantly higher compared to normal tissues.","https://www.ncbi.nlm.nih.gov/pubmed/31646789","High_Unfavourable",NA,"NA","56956252","ENSG00000240498","MONDO_0002691","CDKN2B-AS1 EXPRESSION NA","pass"
"83","NA","NA","HEPATOCELLULAR CARCINOMA","CCAT2","expression",NA,"tissues",31626095,"Increased expression of long non-coding RNA CCAT2 predicts poorer prognosis in patients with hepatocellular carcinoma.","lncRNA CCAT2 may serve as a potential biomarker for predicting overall survival time in HCC. CCAT2 expression levels were significantly increased in HCC tissues compared to that in their normal . overall survival rate of HCC patients in high CCAT2 expression group markedly decreased as compared with that of low CCAT2 expression group","https://www.ncbi.nlm.nih.gov/pubmed/31626095","High_Unfavourable",NA,"NA","56956252","ENSG00000280997","EFO_0000182","CCAT2 EXPRESSION NA","pass"
"84","NA","NA","LIVER CANCER","CCT3","proteinexpresson/serum-level",NA,"celline",3150142,"CCT3 acts upstream of YAP and TFCP2 as a potential target and tumour biomarker in liver cancer.","CCT3 was positively correlated with YAP and TFCP2, and elevated levels of the CCT3-YAP-TFCP2 axis might be critical for liver malignancy. seral-CCT3 was proven to be a potential biomarker. CCT3 was elevated in liver cancer, and its higher expression was associated with poorer overall survival.","https://www.ncbi.nlm.nih.gov/pubmed/31501420","High_Unfavourable",NA,"NA","56956252","ENSG00000163468","MONDO_0002691","CCT3 PROTEINEXPRESSON/SERUM-LEVEL NA","pass"
"85","NA","NA","HEPATOCELLULAR CARCINOMA","MAT2B","expression",NA,"celllines,patients",31493275,"MAT2B mediates invasion and metastasis by regulating EGFR signaling pathway in hepatocellular carcinoma","study demonstrated that silencing of MAT2B could suppress liver cancer cell migration and invasion through the inhibition of EGFR signaling, which suggested that MAT2B might serve as a new prognostic marker and therapeutic target for HCC.","https://www.ncbi.nlm.nih.gov/pubmed/31493275",NA,NA,"NA","56956252","ENSG00000038274","EFO_0000182","MAT2B EXPRESSION NA","pass"
"86","NA","NA","HEPATOCELLULAR CARCINOMA","CDHR5","expression",NA,"celllines,patients",31482521,"CDHR5 inhibits proliferation of hepatocellular carcinoma and predicts clinical prognosis.","study not only identified CDHR5 as a novel prognostic biomarker in HCC but also provided evidence that CDHR5 can inhibit HCC cell proliferation. CDHR5 was downregulated in HCC tissues compared with adjacent liver tissues.In vitro experiments showed that CDHR5 suppressed the proliferation capacity of HCC cells.","https://www.ncbi.nlm.nih.gov/pubmed/31482521","High_favourable",NA,"NA","56956252","ENSG00000099834","EFO_0000182","CDHR5 EXPRESSION NA","pass"
"87","NA","NA","HEPATOCELLULAR CARCINOMA","lncRNA-D16366","RNA",NA,"Patients",31475695,"lncRNA-D16366 Is a Potential Biomarker for Diagnosis and Prognosis of Hepatocellular Carcinoma.","lncRNA-D16366 was decreased in HCC, and might be an independent diagnostic and prognostic indicator in the disease.lncRNA-D16366 was proved to be decreased in the tissues and serum among patients with HCC compared with the corresponding controls.","https://www.ncbi.nlm.nih.gov/pubmed/31475695","Low_Unfavourable",NA,"NA","56956252","NA","EFO_0000182","LNCRNA-D16366 RNA NA","failed biomarker"
"88","NA","NA","HEPATOCELLULAR CARCINOMA","miR-155, miR-96,miR-99a","RNA,RNA,RNA",NA,"Patients",31452818,"miR-155, miR-96 and miR-99a as potential diagnostic and prognostic tools for the clinical management of hepatocellular carcinoma.","The expression levels of miR-155 and miR-96 were upregulated in the tissues and serum of patients with HCC, whereas miR-99a expression levels were decreased. ROC) curve analysis revealed that circulating miR-155, miR-96, miR-99a and a combination of these three miRNAs could serve as diagnostic biomarkers for HCC","https://www.ncbi.nlm.nih.gov/pubmed/31452818","High_Unfavourable,High_Unfavourable,Low_Unfavourable",NA,"NA","56956252","NA, ENSG00000240682, NA","EFO_0000182","failed","failed biomarker,failed term"
"89","NA","NA","HEPATOCELLULAR CARCINOMA","miRNA-122,miRNA-224","RNA,RNA",NA,"Patients",31450927,"Diagnostic Performance of microRNA-122 and microRNA-224 in Hepatitis C Virus-Induced Hepatocellular Carcinoma (HCC).","levels of miRNA-122 were significantly lower in HCC group compared to the cirrhosis group and controls, while levels of miRNA-224 were significantly higher. combining any one of these miRNAs with alpha-fetoprotein will increase the diagnostic accuracy compared to using each marker alone.
miRNA-122 and miRNA-224 could serve as biomarkers for the diagnosis of HCC.","https://www.ncbi.nlm.nih.gov/pubmed/31450927","Low_Unfavourable,High_Unfavourable",NA,"NA","56956252","NA, NA","EFO_0000182","failed","failed biomarker,failed term"
"90","NA","NA","HEPATOCELLULAR CARCINOMA","ATAD3A , ATAD3B","expression,expression",NA,"Patients",31423190,"Prognostic value of ATAD3 gene cluster expression in hepatocellular carcinoma.","ATAD3A and ATAD3B may serve as potential prognostic biomarkers for patients with HCC. high ATAD3A and ATAD3B expression had reduced OS rates compared with patients with low ATAD3A and ATAD3B expression","https://www.ncbi.nlm.nih.gov/pubmed/31423190","High_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000197785, ENSG00000160072","EFO_0000182","failed","failed term"
"91","NA","NA","HEPATOCELLULAR CARCINOMA","miR-182,miR-122-5P","RNA,RNA",NA,"rat",31373075,"Serum miR-182 is a predictive biomarker for dichotomization of risk of hepatocellular carcinoma in rats.","CONCLUSION:","https://www.ncbi.nlm.nih.gov/pubmed/31373075","High_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000207990, NA","EFO_0000182","failed","failed term"
"92","NA","NA","HEPATOCELLULAR CARCINOMA","X91348","RNA/expression",NA,"NA",31349749,"The expression level and clinical significance of lncRNA X91348 in hepatocellular carcinoma.","X91348 expression was decreased in patients with HCC compared with healthy controls","https://www.ncbi.nlm.nih.gov/pubmed/31349749","Low_favourable",NA,"NA","56956252","ENSG00000237517","EFO_0000182","X91348 RNA/EXPRESSION NA","pass"
"93","NA","NA","INTRAHEPATIC CHOLANGIOCARCINOMA","CHD1L","expression",NA,"NA",31173252,"CHD1L is associated with poor survival and promotes the proliferation and metastasis of intrahepatic cholangiocarcinoma.","miRNA-122 and miRNA-224 could serve as biomarkers for the diagnosis of HCC.","https://www.ncbi.nlm.nih.gov/pubmed/31173252","High_Unfavourable",NA,"NA","56956252","ENSG00000131778","EFO_1001961","CHD1L EXPRESSION NA","pass"
"94","NA","NA","HEPATOCELLULAR CARCINOMA","miR-484,TUSC5","RNA,expression",NA,"NA",31157375,"Dysregulation of miR484-TUSC5 axis takes part in the progression of hepatocellular carcinoma."," miR-484/TUSC5 is potential diagnostic biomarkers and therapy targets for HCC. We demonstrated that miR-484 was significantly up-regulated in HCC, while TUSC5 was down-regulated.","https://www.ncbi.nlm.nih.gov/pubmed/31157375","High_Unfavourable,Low_Unfavourable",NA,"NA","56956252","NA, ENSG00000184811","EFO_0000182","failed","failed biomarker,failed term"
"95","NA","NA","HEPATOCELLULAR CARCINOMA","TRMT6","expression",NA,"Patients",31128068,"Clinical Significance of TRMT6 in Hepatocellular Carcinoma: A Bioinformatics-Based Study.","TRMT6 was significantly upregulated in primary HCC tissues. Kaplan-Meier survival curves revealed that higher TRMT6 expression was associated with reduced RFS (p=0.0146) and OS (p=0.0224) in HCC patients. TRMT6 might be a promising prognostic biomarker for poor clinical outcomes in primary HCC patients.","https://www.ncbi.nlm.nih.gov/pubmed/31128068","High_Unfavourable",NA,"NA","56956252","ENSG00000089195","EFO_0000182","TRMT6 EXPRESSION NA","pass"
"96","NA","NA","CHOLANGIOCARCINOMA","EZH2,SUZ12","expression,expression",NA,"Patients",31126817,"Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.","The expression of EZH2 and SUZ12 in CCA tissue was significantly higher than that in adjacent non-cancerous tissue . overexpression of the PRC2 key components especially EZH2 in both nucleus and cytoplasm can be potentially used as a prognostic marker for CCA.","https://www.ncbi.nlm.nih.gov/pubmed/31126817","High_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000106462, ENSG00000178691","EFO_0005221","failed","failed term"
"97","NA","NA","HEPATOCELLULAR CARCINOMA","ZNF207","protein expression",NA,"Patients",31113916,"Expression of ZNF207 in hepatocellular carcinoma and its significance.","patients with high ZNF207 expression had poorer overall survival (OS) and disease-free survival (DFS) than those with the low ZNF207 expression (P<0.01), and ZNF207 was an independent risk factor for OS and DFS of HCC","https://www.ncbi.nlm.nih.gov/pubmed/31113916","High_Unfavourable",NA,"NA","56956252","ENSG00000010244","EFO_0000182","ZNF207 PROTEIN EXPRESSION NA","pass"
"98","NA","NA","HEPATOCELLULAR CARCINOMA","SPG20","methylation",NA,"Patient tissues",31109594,"Aberrant methylation status of SPG20 promoter in hepatocellular carcinoma: A potential tumor metastasis biomarker.","hypermethylation status of SPG20 gene promoter is significantly associated with intra-hepatic metastasis and contribute to HCC metastasis","https://www.ncbi.nlm.nih.gov/pubmed/31109594","High_Unfavourable",NA,"NA","56956252","ENSG00000133104","EFO_0000182","SPG20 METHYLATION NA","pass"
"99","NA","NA","HBV-HEPATOCELLULAR CARCINOMA","LINC01152","RNA",NA,"cells,tissues,mouse",31054511,"HBx-related long non-coding RNA 01152 promotes cell proliferation and survival by IL-23 in hepatocellular carcinoma.","The overexpression of LINC01152 could increases HCC cell proliferation and promotes tumor formation in nude mice. Our findings suggest that LINC01152 plays an important role in HBV-related hepatocellular carcinoma development and may serve as a therapeutic marker for hepatocellular carcinoma.","https://www.ncbi.nlm.nih.gov/pubmed/31054511","High_Unfavourable",NA,"NA","56956252","ENSG00000256124","EFO_0000707","LINC01152 RNA NA","pass"
"100","NA","NA","INTRAHEPATIC CHOLANGIOCARCINOMA","R132xIDH1m","mutation",NA,"Patient, tissues",30935002,"Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients.","Hotspot codon 132 mutations (R132xIDH1m) are frequent in intrahepatic cholangiocarcinoma (ICC), are druggable by anti-IDH1m agents, and could represent a marker of disease progression.","https://www.ncbi.nlm.nih.gov/pubmed/30935002",NA,NA,"NA","56956252","NA","EFO_1001961","R132XIDH1M MUTATION NA","failed biomarker"
"101","SORAFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","AR,epCAM","expression,expression",NA,NA,32132025,"Androgen Receptor Enhances the Efficacy of Sorafenib Against Hepatocellular Carcinoma Through Enriched EpCAM Stemness.","AR+/EpCAM+ may be a marker of responsiveness to sorafenib for patients with HCC. EpCAM+ cells were significantly reduced in AR-knockout mice compared to wild-type HCCs.Regarding sorafenib cytotoxicity, AR-expressing cells were vulnerable to treatment.","https://www.ncbi.nlm.nih.gov/pubmed/32132025","High_Unfavourable,High_Unfavourable",NA,"DB00398","406563","ENSG00000169083, ENSG00000119888","EFO_0000182","failed","failed term"
"102","NA","NA","LIVER CANCER","miR-18a , miR-25","RNA,RNA",NA,"Patients",32051807,"Role of miR-18a and miR-25 disruption and its mechanistic pattern in progression of liver cancer.","biopsy samples from liver cancer patients indicated that both miR-18a and miR-25 were overexpressed during the early stages of liver cancer. Our findings clearly indicate that miR-18a and miR-25 can be used as prognostic biomarkers for early-stage liver cancer.","https://www.ncbi.nlm.nih.gov/pubmed/32051807","High_Unfavourable,High_Unfavourable",NA,"NA","56956252","NA, NA","MONDO_0002691","failed","failed biomarker,failed term"
"103","NA","NA","HEPATOCELLULAR CARCINOMA","RAB34","DNA copy/protein expression",NA,"Patients",29048615,"Overexpression of RAB34 correlates with poor prognosis and tumor progression in hepatocellular carcinoma.","both DNA copy and protein level of RAB34 were upregulating in human hepatocellular carcinoma (HCC) tissues when compared with that in adjacent tissues. patients with overexpression of RAB34 consistently had large tumor size, vessel invasion and poor tumor grade. Furthermore, overall survival analysis showed that patients with upregulated expression of RAB34 were associated with poor prognosis.","https://www.ncbi.nlm.nih.gov/pubmed/29048615","High_Unfavourable",NA,"NA","56956252","ENSG00000109113","EFO_0000182","RAB34 DNA COPY/PROTEIN EXPRESSION NA","pass"
"104","NA","NA","HEPATOCELLULAR CARCINOMA","LINC00473 , FOXP1,miR-345-5p","RNA,Protein,RNA",NA,"celline",32021265,"High Expression B3GAT3 Is Related with Poor Prognosis of Liver Cancer.","LINC00473 contributed to radioresistance in HCC via modulating the miR-345-5p/FOXP1 axis, which might provide a promising diagnostic marker for HCC radiotherapy. Depletion of LINC00473 inhibited proliferation and heightened radiosensitivity and apoptosis in HCC cells. LINC00473 and FOXP1 were up-regulated, while miR-345-5p was down-regulated in HCC tissues and cells.","https://www.ncbi.nlm.nih.gov/pubmed/32021265","High_Unfavourable,High_Unfavourable,Low_Unfavourable",NA,"NA","56956252","NA, ENSG00000114861, NA","EFO_0000182","failed","failed biomarker,failed term"
"105","NA","NA","HEPATOCELLULAR CARCINOMA","CD44, musashi1","expression,protein expression",NA,"celline",31888604,"Upregulation of musashi1 increases malignancy of hepatocellular carcinoma via the Wnt/β-catenin signaling pathway and predicts a poor prognosis.","Upregulation of musashi1 could enhance malignant development of HCC cells and thus might be a novel marker for HCC therapy.  there was a positive correlation between CD44 and musashi1 expression.","https://www.ncbi.nlm.nih.gov/pubmed/31888604","High_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000026508, NA","EFO_0000182","failed","failed term"
"106","NA","NA","HEPATOCELLULAR CARCINOMA","c-Met","expression",NA,"tissues",31846974,"Expression of c-Met in Primary and Recurrent Hepatocellular Carcinoma.","High expression of c-Met may be a prognostic factor for a good, rather than a poor, HCC prognosis.","https://www.ncbi.nlm.nih.gov/pubmed/31846974","High_favourable",NA,"NA","56956252","ENSG00000105976","EFO_0000182","C-MET EXPRESSION NA","pass"
"107","NA","NA","HEPATOCELLULAR CARCINOMA","P-glycoprotein","protein expression",NA,"Patients",8763260,"Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis.","Expression of P-glycoprotein in HCCs is associated with a shorter disease-free interval and shorter survival time.","https://www.ncbi.nlm.nih.gov/pubmed/8763260","Postive unfavourable",NA,"NA","56956252","ENSG00000005471","EFO_0000182","P-GLYCOPROTEIN PROTEIN EXPRESSION NA","pass"
"108","NA","NA","HEPATOCELLULAR CARCINOMA","TGM3","expression",NA,"Patients",31822388,"TGM3 promotes epithelial-mesenchymal transition and hepatocellular carcinogenesis and predicts poor prognosis for patients after curative resection.","TGM3 potentially enhances HCC metastasis. TGM3 may serve as a novel therapeutic target in HCC. Higher expression of TGM3 predicts poor prognosis in HCC patients. TGM3 knockdown led to decreased HCC cell proliferation, invasion, and xenograft tumour growth.","https://www.ncbi.nlm.nih.gov/pubmed/31822388","High_Unfavourable",NA,"NA","56956252","ENSG00000125780","EFO_0000182","TGM3 EXPRESSION NA","pass"
"109","NA","NA","HEPATOCELLULAR CARCINOMA","nm23-H1","expression",NA,"Patients",7530600,"NM23-H1 and NM23-H2 messenger RNA abundance in human hepatocellular carcinoma.","nm23-H1 mRNA abundance may be a predictor of intrahepatic metastasis, the most important factor correlated with the metastatic potential of hepatocellular carcinoma.","https://www.ncbi.nlm.nih.gov/pubmed/7530600",NA,NA,"NA","56956252","ENSG00000239672","EFO_0000182","NM23-H1 EXPRESSION NA","pass"
"110","NA","NA","HEPATOCELLULAR CARCINOMA","CD15","protein expression",NA,"Patients",7685236,"Expression of the CD15 antigen in hepatocellular carcinoma.","CD15-positive HCC had histologic intrahepatic metastasis more often than did CD15-negative HCC. The survival rate of patients with CD15-negative HCC was better than that of patients with CD15-positive HCC,","https://www.ncbi.nlm.nih.gov/pubmed/7685236","Postive unfavourable",NA,"NA","56956252","ENSG00000177697","EFO_0000182","CD15 PROTEIN EXPRESSION NA","pass"
"111","NA","NA","HEPATOCELLULAR CARCINOMA","Ki67, c-met protooncogene","expression,protein expression",NA,"Patients",7768498,"Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions.","The percentage of Ki67+ nuclei in high-grade HCCs paralleled c-met protooncogene overexpression.","https://www.ncbi.nlm.nih.gov/pubmed/7768498","Postive unfavourable, High unfavourable",NA,"NA","56956252","ENSG00000148773, NA","EFO_0000182","failed","failed term"
"112","NA","NA","HEPATOCELLULAR CARCINOMA","CD80","gene expression",NA,"celline",9141426,"Expression of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) on human hepatocellular carcinoma.","the primary cytolytic activity against parental Hep3B cells could be induced effectively by B71-transfected Hep3B cells. B7-1 gene transfer is the best way to induce strong expression of this molecule and this might be useful for immuno-gene therapy against human HCC.","https://www.ncbi.nlm.nih.gov/pubmed/9141426","Positive unfavourable",NA,"NA","56956252","ENSG00000121594","EFO_0000182","CD80 GENE EXPRESSION NA","pass"
"113","NA","NA","HEPATOCELLULAR CARCINOMA","ANXA3","expression",NA,"tissues",24375474,"Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma.","ANXA3 might play an important role in HCC progression and chemoresistance, and could serve as a novel prognostic marker and therapeutic target for HCC.","https://www.ncbi.nlm.nih.gov/pubmed/24375474","High_Unfavourable",NA,"NA","56956252","ENSG00000138772","EFO_0000182","ANXA3 EXPRESSION NA","pass"
"114","SOREFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","pERK,VEGFR-2","expression,expression",NA,"Patients",25559745,"Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.","Elevated tissue expression of pERK and VEGFR-2 was predictive of poor outcome in advanced HCC treated with sorafenib.","https://www.ncbi.nlm.nih.gov/pubmed/25559745",NA,NA,"NA","NA","ENSG00000172071, ENSG00000128052","EFO_0000182","failed","failed drug,failed term"
"115","NA","NA","HEPATOCELLULAR CARCINOMA","UBE4B","expression",NA,"celline",25557723,"Expression and prognostic role of ubiquitination factor E4B in primary hepatocellular carcinoma.","UBE4B might have an oncogenic role in human primary HCC, and that it could be used as a prognostic marker (as well as a potential molecular target) for the treatment of HCC. Amplified expression of UBE4B was highly correlated with poor outcome.","https://www.ncbi.nlm.nih.gov/pubmed/25557723","High_Unfavourable",NA,"NA","56956252","ENSG00000130939","EFO_0000182","UBE4B EXPRESSION NA","pass"
"116","NA","NA","HEPATOCELLULAR CARCINOMA","FVII","expression",NA,"tissues",27551480,"Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling","FVII expression in HCC may be useful as a prognostic indicator in patients with HCC","https://www.ncbi.nlm.nih.gov/pubmed/27551480","High_Unfavourable",NA,"NA","56956252","ENSG00000057593","EFO_0000182","FVII EXPRESSION NA","pass"
"117","NA","NA","HEPATOCELLULAR CARCINOMA","miR-744","expression",NA,"Patient, tissues",25543521,"miR-744 is a potential prognostic marker in patients with hepatocellular carcinoma.","associate decreased miR-744 expression with HCC recurrence and prognosis, and also suggest that miR-744 is an independent predictor of survival in HCC patients after LT and may therefore be a potential biomarker for their prognosis. Patients with lower miR-744 expression showed significantly poorer recurrence-free survival and OS than individuals with higher miR-744 levels.","https://www.ncbi.nlm.nih.gov/pubmed/25543521","Low_Unfavourable",NA,"NA","56956252","NA","EFO_0000182","MIR-744 EXPRESSION NA","failed biomarker"
"118","SORAFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","PD1, CXCR4","expression,expression",NA,"mouse",25529917,"CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.","Anti-PD-1 treatment can boost antitumor immune responses in HCC models; when used in combination with sorafenib, anti-PD-1 immunotherapy shows efficacy only with concomitant targeting of the hypoxic and immunosuppressive microenvironment with agents such as CXCR4 inhibitors.","https://www.ncbi.nlm.nih.gov/pubmed/25529917","High_Unfavourable,High_Unfavourable",NA,"DB00398","406563","ENSG00000145335, ENSG00000121966","EFO_0000182","failed","failed term"
"119","NA","NA","HEPATOCELLULAR CARCINOMA","TLR4","expression",NA,"cellline,mouse",25511737,"Toll like receptor 4 facilitates invasion and migration as a cancer stem cell marker in hepatocellular carcinoma.","TLR4 may act as a CSC marker, prompting tumor invasion and migration, which contributes to the poor prognosis of HCC.","https://www.ncbi.nlm.nih.gov/pubmed/25511737","High_Unfavourable",NA,"NA","56956252","ENSG00000136869","EFO_0000182","TLR4 EXPRESSION NA","pass"
"120","NA","NA","HEPATOCELLULAR CARCINOMA","MCT4","expression",NA,"Patient tissues,Celllines",25446815,"Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration.","high MCT4 expression is indicative of elevated alpha fetoprotein levels and larger tumor size, which leads to poorer disease-free survival (DFS) and overall survival (OS).","https://www.ncbi.nlm.nih.gov/pubmed/25446815","High_Unfavourable",NA,"NA","56956252","ENSG00000141526","EFO_0000182","MCT4 EXPRESSION NA","pass"
"121","YM155","Survivin","HEPATOCELLULAR CARCINOMA","Survivin","expression",NA,"Patient tissues,Celllines",25714025,"The over-expression of survivin enhances the chemotherapeutic efficacy of YM155 in human hepatocellular carcinoma.","results clearly demonstrated that the level of survivin and p-survivin expression could serve as molecular predictive biomarkers to select potential YM155-responsive patients, in a move towards delivering precision medicine for HCC patients.","https://www.ncbi.nlm.nih.gov/pubmed/25714025","High_Unfavourable",NA,"NA","11178236","ENSG00000089685","EFO_0000182","SURVIVIN EXPRESSION NA","pass"
"122","NA","NA","HEPATOCELLULAR CARCINOMA","CD90,CXCR4","expression,expression",NA,"celline",25672610,"Evidence of CD90+CXCR4+ cells as circulating tumor stem cells in hepatocellular carcinoma.","CD90+CXCR4+ HCC cells may be CTSCs and selective elimination of these cells may substantially improve the current HCC therapy by","https://www.ncbi.nlm.nih.gov/pubmed/25672610","Positive unfavourable, Positive unfavourable",NA,"NA","56956252","ENSG00000154096, ENSG00000121966","EFO_0000182","failed","failed term"
"123","NA","NA","HEPATOCELLULAR CARCINOMA","Kindlin-1","RNA/protein expression",NA,"Patient tissues",25592379,"Expression of Kindlin-1 in human hepatocellular carcinoma and its prognostic significance.","Kindlin-1 expression was higher in HCC tumor tissues relative to that in adjacent normal tissue at the both mRNA and protein levels. our data suggest that Kindlin-1 could play an important role in HCC and might serve as a promising prognostic marker and potential target for HCC therapy","https://www.ncbi.nlm.nih.gov/pubmed/25592379","High_Unfavourable",NA,"NA","56956252","ENSG00000101311","EFO_0000182","KINDLIN-1 RNA/PROTEIN EXPRESSION NA","pass"
"124","NA","ADAM8","HEPATOCELLULAR CARCINOMA","ADAM8","expression",NA,"Mouse",25585999,"The important role of ADAM8 in the progression of hepatocellular carcinoma induced by diethylnitrosamine in mice.","Anti-ADAM8 mAb intervention might be suitable as a potential method for HCC therapy.","https://www.ncbi.nlm.nih.gov/pubmed/25585999","High_Unfavourable",NA,"NA","56956252","ENSG00000151651","EFO_0000182","ADAM8 EXPRESSION NA","pass"
"125","NA","NA","HEPATOCELLULAR CARCINOMA","SQLE","expression",NA,"NA",25787749,"Squalene epoxidase (SQLE) promotes the growth and migration of the hepatocellular carcinoma cells.","overexpression of SQLE in HCC cells promoted cell proliferation and migration, while downregulation of SQLE inhibited the tumorigenicity of HCC cells in vitro and in vivo","https://www.ncbi.nlm.nih.gov/pubmed/25787749","High_Unfavourable",NA,"NA","56956252","ENSG00000104549","EFO_0000182","SQLE EXPRESSION NA","pass"
"126","ASTEMIZOLE","Eag1","HEPATOCELLULAR CARCINOMA","Eag1","expression",NA,"celline",25783527,"Astemizole-based anticancer therapy for hepatocellular carcinoma (HCC), and Eag1 channels as potential early-stage markers of HCC.","Astemizole might have clinical utility for HCC prevention and treatment, and Eag1 channels may be potential early HCC biomarkers","https://www.ncbi.nlm.nih.gov/pubmed/25783527","High_Unfavourable",NA,"DB00637","2247","ENSG00000143473","EFO_0000182","EAG1 EXPRESSION NA","pass"
"127","NA","NA","HEPATOCELLULAR CARCINOMA","VEGF","serum-level",NA,"patients",25862879,"VEGF in patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy.","Monitoring the serum VEGF level is useful for predicting the response of aHCC to HAIC, as well as for predicting metastasis, tumor type and vascular invasion.","https://www.ncbi.nlm.nih.gov/pubmed/25862879","High_Unfavourable",NA,"NA","56956252","ENSG00000112715","EFO_0000182","VEGF SERUM-LEVEL NA","pass"
"128","NA","NA","HEPATOCELLULAR CARCINOMA","FGFR2","expression",NA,"Patients",25834803,"Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma.","FGFR2 expression in HCC could be a prognostic indicator of postsurgical survival. FGFR2 positivity in HCC was associated with a significantly shorter overall survival","https://www.ncbi.nlm.nih.gov/pubmed/25834803","High_Unfavourable",NA,"NA","56956252","ENSG00000066468","EFO_0000182","FGFR2 EXPRESSION NA","pass"
"129","NA","NA","HEPATOCELLULAR CARCINOMA","FOXF2","expression",NA,"celllines,patients",25824262,"Loss of FOXF2 Expression Predicts Poor Prognosis in Hepatocellular Carcinoma Patients.","FOXF2 may serve as a prognostic biomarker for HCC and may be a promising target in the treatment of patients with HCC. FOXF2 downregulation was observed in HCC tissues (p < 0.001) compared with peritumorous tissues, and its expression levels were closely correlated with overall survival and recurrence-free survival","https://www.ncbi.nlm.nih.gov/pubmed/25824262","Low_Unfavourable",NA,"NA","56956252","ENSG00000137273","EFO_0000182","FOXF2 EXPRESSION NA","pass"
"130","NA","NA","HEPATOCELLULAR CARCINOMA","SAMSN1","expression",NA,"Patient tissues,Celllines",25805236,"Suppression of SAMSN1 Expression is Associated with the Malignant Phenotype of Hepatocellular Carcinoma.","inhibition of SAMSN1 transcription through DNA hypermethylation may influence the progression of HCC and thus represent a novel biomarker of the phenotype of HCC cells. levels of SAMSN1 mRNA in HCC tissues inversely correlated with tumor size. SAMSN1 was expressed at significantly lower levels in tumor tissue compared with the corresponding noncancerous tissues of patients with HCC.","https://www.ncbi.nlm.nih.gov/pubmed/25805236","Low_Unfavourable",NA,"NA","56956252","ENSG00000155307","EFO_0000182","SAMSN1 EXPRESSION NA","pass"
"131","NA","NA","HEPATOCELLULAR CARCINOMA","PKM2","expression",NA,"Patient tissues,Celllines",25788265,"Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.","PKM2 serves as a promising biomarker for poor prognosis of patients with HCC and its knockdown induces HCC apoptosis by stabilizing Bim. The knockdown of PKM2 in HCC cells inhibited cell proliferation and induced apoptosis in vitro and in vivo.","https://www.ncbi.nlm.nih.gov/pubmed/25788265","High_Unfavourable",NA,"NA","56956252","ENSG00000067225","EFO_0000182","PKM2 EXPRESSION NA","pass"
"132","NA","NA","CHOLANGIOCARCINOMA","Fascin","expression",NA,"celline",25882880,"Fascin Overexpression Promotes Cholangiocarcinoma RBE Cell Proliferation, Migration, and Invasion.","study provides evidence for fascin as a potential target in the treatment of cholangiocarcinoma.","https://www.ncbi.nlm.nih.gov/pubmed/25882880","High_Unfavourable",NA,"NA","56956252","ENSG00000186765","EFO_0005221","FASCIN EXPRESSION NA","pass"
"133","NA","NA","HEPATOCELLULAR CARCINOMA","PTMA","expression",NA,"Patient tissues",25865690,"Expression of prothymosin alpha predicts early recurrence and poor prognosis of hepatocellular carcinoma.","PTMA protein expression might be a novel predictor of early recurrence and RFS in HCC patients, e PTMA could be used as an immunohistochemical biomarker to detect patients with a high risk of recurrence.","https://www.ncbi.nlm.nih.gov/pubmed/25865690","Positive unfavourable",NA,"NA","56956252","ENSG00000187514","EFO_0000182","PTMA EXPRESSION NA","pass"
"134","NA","NA","HEPATOCELLULAR CARCINOMA","GPC3","expression",NA,"Patient tissues",25865688,"Prognostic value of glypican-3 in patients with HBV-associated hepatocellular carcinoma after liver transplantation.","GPC-3 is a potential biomarker for poor prognosis after LT in HCC patients with HBV-associated cirrhosis.","https://www.ncbi.nlm.nih.gov/pubmed/25865688","High_Unfavourable",NA,"NA","56956252","ENSG00000147257","EFO_0000182","GPC3 EXPRESSION NA","pass"
"135","NA","NA","HEPATOCELLULAR CARCINOMA","K19","expression",NA,"cellines,tissues",26011233,"Keratin 19 protein expression is an independent predictor of survival in human hepatocellular carcinoma.","Our study confirms the prognostic significance of K19 expression in Caucasian patients with HCCs, providing further evidence that it may be used to stratify HCC according to tumour aggressiveness. K19 positivity and microvascular invasion were found to be associated with decreased recurrence-free survival (P<0.001 and P=0.004, respectively) and overall survival","https://www.ncbi.nlm.nih.gov/pubmed/26011233","Positive unfavourable",NA,"NA","56956252","ENSG00000171345","EFO_0000182","K19 EXPRESSION NA","pass"
"136","NA","NA","HEPATOCELLULAR CARCINOMA","miR-212,FOXA1","RNA,expression",NA,"celline",25965836,"MicroRNA-212 suppresses tumor growth of human hepatocellular carcinoma by targeting FOXA1","miR-212 may serve as a prognostic indicator for HCC patients and exerts tumor suppressive role, at least in part, by inhibiting FOXA1. miR-212 inhibited tumor growth of HCC via suppressing proliferation and inducing apoptosis. Furthermore, we confirmed that Forkhead box protein A1 (FOXA1) was a direct target of miR-212, and it abrogated the function of miR-212 in HCC.","https://www.ncbi.nlm.nih.gov/pubmed/25965836","High_favourable,High_Unfavourable",NA,"NA","56956252","NA, ENSG00000129514","EFO_0000182","failed","failed biomarker,failed term"
"137","SOREFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","TGFB1","expression",NA,"celline",25977342,"High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib.","In preclinical models of HCC, higher TGF-β1 expression levels were associated with poorer sensitivity to sorafenib.","https://www.ncbi.nlm.nih.gov/pubmed/25977342","High_Unfavourable",NA,"NA","NA","ENSG00000105329","EFO_0000182","TGFB1 EXPRESSION NA","failed drug"
"138","NA","NA","HEPATOCELLULAR CARCINOMA","AEG-1","expression",NA,"Mouse",26035424,"The emerging role of astrocyte-elevated gene-1 in hepatocellular carcinoma (Review).","AEG-1 in HCC, indicating its key roles and potential as a biomarker or significant target for the therapy of HCC.","https://www.ncbi.nlm.nih.gov/pubmed/26035424","High_Unfavourable",NA,"NA","56956252","ENSG00000147649","EFO_0000182","AEG-1 EXPRESSION NA","pass"
"139","NA","NA","HEPATOCELLULAR CARCINOMA","MiR-20a","expression",NA,"Patient tissues",26031366,"MiR-20a Induces Cell Radioresistance by Activating the PTEN/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.","MiR-20a induces HCC cell radioresistance by activating the PTEN/PI3K/Akt pathway, which suggests that miR-20a/PTEN/PI3K/Akt might represent a target of investigation for developing effective therapeutic strategies against HCC.","https://www.ncbi.nlm.nih.gov/pubmed/26031366","High_Unfavourable",NA,"NA","56956252","NA","EFO_0000182","MIR-20A EXPRESSION NA","failed biomarker"
"140","NA","NA","HEPATOCELLULAR CARCINOMA","ANXA2","expression",NA,"Patient tissues",26109000,"Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma.","ANXA2 up-regulation might represent an acquired metastasis phenotype of HCC, help to screen out high-risk population for HCC, or more effectively treat a subset of postsurgical HCC patients positive for ANXA2.","https://www.ncbi.nlm.nih.gov/pubmed/26109000","High_Unfavourable",NA,"NA","56956252","ENSG00000182718","EFO_0000182","ANXA2 EXPRESSION NA","pass"
"141","NA","NA","HEPATOCELLULAR CARCINOMA","PCAT-1","expression",NA,"Patient tissues",26097602,"Prognostic significance of long non-coding RNA PCAT-1 expression in human hepatocellular carcinoma.","increased expression of PCAT-1 was associated with advanced clinical parameters and poor overall survival of HCC patients, indicating that PCAT-1 up-regulation may serve as a novel biomarker of poor prognosis in HCC patients.","https://www.ncbi.nlm.nih.gov/pubmed/26097602","High_Unfavourable",NA,"NA","56956252","ENSG00000253438","EFO_0000182","PCAT-1 EXPRESSION NA","pass"
"142","NA","NA","HEPATOCELLULAR CARCINOMA","MAGE-A3, MAGE-A4 ,NY-ESO-1","expression,expression,expression",NA,"Patient tissues",26097535,"Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinoma.","The combinatorial expression of CTAs-A3/A4/NY mRNA promotes the predictive accuracy of HCC recurrence and itself may be a potential target for immunotherapy of HCC as well.","https://www.ncbi.nlm.nih.gov/pubmed/26097535","High_Unfavourable,High_Unfavourable,High_Unfavourable",NA,"NA","56956252","NA, NA, ENSG00000184033","EFO_0000182","failed","failed biomarker,failed term"
"143","NA","NA","HEPATOCELLULAR CARCINOMA","TMPRSS4","expression",NA,"Patient tissues",26190376,"TMPRSS4 facilitates epithelial-mesenchymal transition of hepatocellular carcinoma and is a predictive marker for poor prognosis of patients after curative resection.","increase of TMPRSS4 expression may be a key event for HCC progression and may be regarded as a potential prognostic marker for HCC.","https://www.ncbi.nlm.nih.gov/pubmed/26190376","High_Unfavourable",NA,"NA","56956252","ENSG00000137648","EFO_0000182","TMPRSS4 EXPRESSION NA","pass"
"144","NA","NA","HEPATOCELLULAR CARCINOMA","miR-503,PRMT1","RNA,expression",NA,"cellines,tissues",26163260,"miR-503 suppresses metastasis of hepatocellular carcinoma cell by targeting PRMT1.","miR-503-mediated PRMT1 could also emerge as a potential important biomarker for HCC. miR-503 suppresses cell metastasis in HCC through targeting the protein arginine methyl transferase 1 (PRMT1) mRNA. exogenous expression of miR-503 dramatically suppressed epithelial-mesenchymal transition (EMT) via PRMT1 in HCC cells.","https://www.ncbi.nlm.nih.gov/pubmed/26163260","High_favourable,High_Unfavourable",NA,"NA","56956252","NA, ENSG00000126457","EFO_0000182","failed","failed biomarker,failed term"
"145","NA","NA","HEPATOCELLULAR CARCINOMA","ALDH1A1","expression",NA,"Patient tissues",26160842,"ALDH1A1-overexpressing cells are differentiated cells but not cancer stem or progenitor cells in human hepatocellular carcinoma.","The ALDH1A1-high group was significantly associated with low serum levels of α-fetoprotein, small tumor diameter, very little lymphovascular invasion, more differentiated pathology and good stage. The ALDH1A1-high group showed more favorable prognosis for recurrence-free survival.","https://www.ncbi.nlm.nih.gov/pubmed/26160842","High_favourable,High_Favourable,High_Favourable,High_Favourable,High_Favourable,High_Favourable,High_Favourable,High_Favourable,High_Favourable, Unfavourable, Favourable",NA,"NA","56956252","ENSG00000165092","EFO_0000182","ALDH1A1 EXPRESSION NA","pass"
"146","CISPLATIN","NA","HEPATOCELLULAR CARCINOMA","miR-363,MCL1","expression,expression",NA,"celline",26143754,"Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1.","miR-363 levels were significantly decreased in HCC patients treated with cisplatin-based chemotherapy. MiR-363 levels were also lower in cisplatin-resistant HepG2 (HepG2-R) cells than in HepG2 cells. Exogenous miR-363 significantly overcame cisplatin resistance in HepG2-R cells, whereas miR-363 knockdown increased the cell viability during cisplatin treatment. Downregulation of miR-363 resulted in upregulation of Mcl-1","https://www.ncbi.nlm.nih.gov/pubmed/26143754","Low_unfavourable, High_unfavourable",NA,"DB00515","135804801","ENSG00000284499, ENSG00000143384","EFO_0000182","failed","failed term"
"147","NA","NA","COMBINED HEPATOCELLULAR CHOLANGIOCARCINOMA","CD44","expression",NA,"Patient tissues",26131439,"CD44 expression in patients with combined hepatocellular cholangiocarcinoma.","The expression of cancer stem cell marker CD44 was associated with poor prognosis in patients with ChC.","https://www.ncbi.nlm.nih.gov/pubmed/26131439","High_Unfavourable",NA,"NA","56956252","ENSG00000026508","EFO_0000707","CD44 EXPRESSION NA","pass"
"148","NA","NA","HEPATOCELLULAR CARCINOMA","FAM83D","expression",NA,"Patient tissues,Celllines",26125229,"Upregulation of FAM83D affects the proliferation and invasion of hepatocellular carcinoma.","Knocking down FAM83D significantly promoted the growth of Huh7 and HepG2 cells, as demonstrated in an RNA interference assay. Moreover, the DNA methylation status of the FAM83D promoter was significantly reduced in the HCC specimens with overexpression of FAM83D gene. Our data suggest that the upregulation of FAM83D, a potential oncotarget gene, may be triggered by epigenetic events and can contribute to hepatocarcinogenesis.","https://www.ncbi.nlm.nih.gov/pubmed/26125229","High_Unfavourable",NA,"NA","56956252","ENSG00000101447","EFO_0000182","FAM83D EXPRESSION NA","pass"
"149","OXALIPLATIN","NA","HEPATOCELLULAR CARCINOMA","HOX8","expression",NA,"Patient tissues,Celllines",26123838,"Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma.","HOXC8 promoted HCC proliferation and predicted poor prognosis. Furthermore, upregulated HOXC8 expression was associated with oxaliplatin resistance in hepatocellular carcinoma.","https://www.ncbi.nlm.nih.gov/pubmed/26123838","High_Unfavourable",NA,"DB00526","71301229","ENSG00000120149","EFO_0000182","HOX8 EXPRESSION NA","pass"
"150","NA","NA","HEPATOCELLULAR CARCINOMA","AJAP1","expression/DNA methylation",NA,"cellines,tissues",26122373,"Reduced Expression of Adherens Junctions Associated Protein 1 Predicts Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy.","Low levels of AJAP1 mRNA in patients with HCC associated significantly with elevated levels of tumor markers, larger tumor size, serosal infiltration, vascular invasion, hypermethylation of the AJAP1 promoter, and copy number loss at AJAP1 locus. Patients with low levels of AJAP1 expression were more likely to experience shorter disease-free survival","https://www.ncbi.nlm.nih.gov/pubmed/26122373","Low_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000196581","EFO_0000182","AJAP1 EXPRESSION/DNA METHYLATION NA","pass"
"151","CISPLATIN","NA","HEPATOCELLULAR CARCINOMA","MCL1","expression",NA,"celline",26219890,"Imperatorin acts as a cisplatin sensitizer via downregulating Mcl-1 expression in HCC chemotherapy.","combination with imperatorin could enhance the antitumor activity of cisplatin via targeting Mcl-1 and reverse the resistance to cisplatin in HCC","https://www.ncbi.nlm.nih.gov/pubmed/26219890","High_Unfavourable",NA,"DB00515","135804801","ENSG00000143384","EFO_0000182","MCL1 EXPRESSION NA","pass"
"152","NA","NA","HEPATOCELLULAR CARCINOMA","KIF1B","expression",NA,"Patient tissues",26217094,"Downregulation of KIF1B mRNA in hepatocellular carcinoma tissues correlates with poor prognosis.","Downregulation of KIF1B in HCC tissues is associated with poor prognosis; additional clinical studies are needed to confirm whether KIF1B can serve as a prognostic marker.","https://www.ncbi.nlm.nih.gov/pubmed/26217094","Low_Unfavourable",NA,"NA","56956252","ENSG00000054523","EFO_0000182","KIF1B EXPRESSION NA","pass"
"153","NA","NA","INTRAHEPATIC CHOLANGIOCARCINOMA","MUC5AC","expression",NA,"Patients",26210654,"Prognostic evaluation of mucin-5AC expression in intrahepatic cholangiocarcinoma, mass-forming type, following hepatectomy.","strong correlation between MUC5AC expression and lymph node metastasis. MUC5AC expression was significantly related to long-term prognosis and aggressive tumor development, and may be a useful prognostic marker","https://www.ncbi.nlm.nih.gov/pubmed/26210654","High_Unfavourable",NA,"NA","56956252","ENSG00000215182","EFO_1001961","MUC5AC EXPRESSION NA","pass"
"154","NA","NA","HEPATOCELLULAR CARCINOMA","Caveolin-1","expression",NA,"cellines,tissues",26206578,"Caveolin-1 promotes tumor growth and metastasis via autophagy inhibition in hepatocellular carcinoma.","Caveolin-1 may function as a novel prognostic indicator for hepatocellular carcinoma patients after curative resection, and combination of targeted therapy aimed at Caveolin-1 and autophagy modulation may represent an effective way to treat hepatocellular carcinoma.","https://www.ncbi.nlm.nih.gov/pubmed/26206578","High_Unfavourable",NA,"NA","56956252","ENSG00000105974","EFO_0000182","CAVEOLIN-1 EXPRESSION NA","pass"
"155","NA","NA","HEPATOCELLULAR CARCINOMA","CXCR4","expression",NA,"celline",26203228,"A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinoma.","CXCR4 is overexpressed in HCC tissues but not in normal hepatic tissue.","https://www.ncbi.nlm.nih.gov/pubmed/26203228","High_Unfavourable",NA,"NA","56956252","ENSG00000121966","EFO_0000182","CXCR4 EXPRESSION NA","pass"
"156","NA","NA","HEPATOCELLULAR CARCINOMA","miRNA-325/HMGB1","RNA/expression",NA,"celline",26194496,"The microRNA-325 inhibits hepatocellular carcinoma progression by targeting high mobility group box 1.","miR-325 regulates cell invasion and proliferation via targeting HMGB1 and may be a potential prognostic marker for HCC. HMGB1 might be a direct target of miR-325 and is negatively regulated by miR-325.","https://www.ncbi.nlm.nih.gov/pubmed/26194496","High_favourable/Low_unfavourable",NA,"NA","56956252","NA","EFO_0000182","MIRNA-325/HMGB1 RNA/EXPRESSION NA","failed biomarker"
"157","NA","NA","HEPATOCELLULAR CARCINOMA","miR-21","expression",NA,"Patient tissues",26261620,"Increased expression of miR-21 predicts poor prognosis in patients with hepatocellular carcinoma.","miR-21 expression was significantly upregulated in HCC tissues when compared with adjacent non-tumor tissues. increased expression of miR-21 was significantly correlated with tumor progression and could be a novel potential biomarker for HCC prognosis.","https://www.ncbi.nlm.nih.gov/pubmed/26261620","High_Unfavourable",NA,"NA","56956252","ENSG00000284190","EFO_0000182","MIR-21 EXPRESSION NA","pass"
"158","NA","NA","HEPATOCELLULAR CARCINOMA","MDR1","expression",NA,"tissues",26261589,"Relationship between the expression of MDR1 in hepatocellular cancer and its biological behaviors.","In MDR1 expressions of HCC patients, the survival curve of the negative is higher than that of the positive. MDR1 expression may play an important role in primary HCC drug resistance","https://www.ncbi.nlm.nih.gov/pubmed/26261589",NA,NA,"NA","56956252","ENSG00000085563","EFO_0000182","MDR1 EXPRESSION NA","pass"
"159","DOXORUBICIN","NA","HEPATOCELLULAR CARCINOMA","SYF2","expression",NA,"cellines,tissues",26260052,"Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma.","SYF2 may be a novel prognostic marker and serve as a potential therapeutic target in HCC. we found that SYF2 might interact with Cyclin D1 and could confer doxorubicin resistance in HCC cells. SYF2 may be a novel prognostic marker and serve as a potential therapeutic target in HCC.","https://www.ncbi.nlm.nih.gov/pubmed/26260052","High_Unfavourable",NA,"DB00997","443939","ENSG00000117614","EFO_0000182","SYF2 EXPRESSION NA","pass"
"160","NA","NA","HEPATOCELLULAR CARCINOMA","GPC3","expression",NA,"Patients,Mouse",26256079,"Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma.","Oncofetal GPC-3 is a highly specific biomarker for the diagnosis of HCC and a promising target molecule for HCC gene therapy.","https://www.ncbi.nlm.nih.gov/pubmed/26256079","High_Unfavourable",NA,"NA","56956252","ENSG00000147257","EFO_0000182","GPC3 EXPRESSION NA","pass"
"161","SORAFENIB","NA","HEPATOCELLULAR CARCINOMA","CD133, IGF2BP3","expression,expression",NA,"celllines,patients",26327240,"An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.","results suggested that the d-ICD may inhibit HCC cells growth by IGF2BP3 decrease and that IGF2BP3 may serve as a therapeutic target for HCC. CSC marker CD133 expression was increased after IGF2BP3 overexpression. high IGF2BP3 expression predicted poor survival in a cohort of 236 patients with HCC","https://www.ncbi.nlm.nih.gov/pubmed/26327240","High_Unfavourable,High_Unfavourable",NA,"DB00398","406563","ENSG00000007062, ENSG00000136231","EFO_0000182","failed","failed term"
"162","NA","NA","CHOLANGIOCARCINOMA","S100P","expression",NA,"Patient tissues,Celllines",26312563,"Significance of S100P as a biomarker in diagnosis, prognosis and therapy of opisthorchiasis-associated cholangiocarcinoma","Extremely high expression of S100P mRNA was detected in the CCA tumor tissues.The increased S100P protein expression was immunohistochemically confirmed and localized in the CCA cytoplasm and/or nuclei.","https://www.ncbi.nlm.nih.gov/pubmed/26312563","High_Unfavourable",NA,"NA","56956252","ENSG00000163993","EFO_0005221","S100P EXPRESSION NA","pass"
"163","NA","NA","HEPATOCELLULAR CARCINOMA","AGX2TL1","expression",NA,"celllines,patients",26294768,"AGXT2L1 is down-regulated in heptocellular carcinoma and associated with abnormal lipogenesis","AGXT2L1 is down-regulated in HCC and its low expression indicates a poor prognosis. Our findings also demonstrated that AGXT2L1 is a crucial gene in the abnormal lipogenesis of HCC tissue.","https://www.ncbi.nlm.nih.gov/pubmed/26294768","Low_Unfavourable",NA,"NA","56956252","NA","EFO_0000182","AGX2TL1 EXPRESSION NA","failed biomarker"
"164","NA","NA","HEPATOCELLULAR CARCINOMA","HAX1","expression",NA,"celllines,patients",26339377,"HAX-1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation.","HAX-1 can be a novel molecular marker for HCC. HAX-1 expression level significantly correlated with clinic outcome of HCC. Cell based assay revealed that knockdown of HAX-1 inhibits cell proliferation.","https://www.ncbi.nlm.nih.gov/pubmed/26339377","High_Unfavourable",NA,"NA","56956252","ENSG00000143575","EFO_0000182","HAX1 EXPRESSION NA","pass"
"165","CISPLATIN","NA","HEPATOCELLULAR CARCINOMA","IP10","expression",NA,"Patients",26336986,"Interferon-gamma inducible protein 10 (IP10) induced cisplatin resistance of HCC after liver transplantation through ER stress signaling pathway.","The overexpression of IP10, which induced by liver graft injury, may lead to cisplatin resistance. rat liver transplantation model, significant up-regulation of IP10 associated with multidrug resistant genes was found in small-for-size liver graft. Clinically, high expression of circulating IP10 was significant correlated with tumor recurrence in HCC patients underwent living donor liver transplantation.","https://www.ncbi.nlm.nih.gov/pubmed/26336986","High_Unfavourable",NA,"DB00515","135804801","ENSG00000169245","EFO_0000182","IP10 EXPRESSION NA","pass"
"166","SOREFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","FGF3,FGF4,VEGFA,phospho-Mapk14,phospho-Atf2","expression,expression,expression expression",NA,"Patients",26420960,"Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?","studies identified tumor amplification of FGF3/FGF4 or VEGFA and tumor expression of phospho-Mapk14 and phospho-Atf2 as possible predictive markers that await validation.","https://www.ncbi.nlm.nih.gov/pubmed/26420960",NA,NA,"NA","NA","ENSG00000186895, ENSG00000075388, ENSG00000112715, NA, NA","EFO_0000182","failed","failed drug,failed term"
"167","NA","NA","HEPATOCELLULAR CARCINOMA","CDT1","expression",NA,"Patient tissues",26408331,"Overexpression of CDT1 Is a Predictor of Poor Survival in Patients with Hepatocellular Carcinoma.","Increased CDT1 expression was associated with higher tumor grade  and tumor-node-metastasis  stage. High CDT1 expression correlated significantly with reduced overall survival. CDT1 overexpression is a significant prognostic biomarker in hepatocellular carcinoma.","https://www.ncbi.nlm.nih.gov/pubmed/26408331","High_Unfavourable",NA,"NA","56956252","ENSG00000167513","EFO_0000182","CDT1 EXPRESSION NA","pass"
"168","CISPLATIN","NA","HEPATOCELLULAR CARCINOMA","OPN","expression",NA,"tissues",26397192,"Overexpression of osteopontin promotes resistance to cisplatin treatment in HCC.","OPN was significantly increased in cisplatin-resistant specimens. blockage of OPN pathway promoted the chemosensitivity of HCC cells to cisplatin","https://www.ncbi.nlm.nih.gov/pubmed/26397192","High_Unfavourable",NA,"DB00515","135804801","ENSG00000118785","EFO_0000182","OPN EXPRESSION NA","pass"
"169","NA","NA","HEPATOCELLULAR CARCINOMA","USP22,Survivin","expression",NA,"Patients",26497847,"Expression of USP22 and Survivin is an indicator of malignant behavior in hepatocellular carcinoma.","USP22 can be useful as a new prognostic marker and therapeutic target in HCC patients. High expression of USP22 and survivin was frequently observed in HCC cases, in comparison with normal adjacent liver tissues.","https://www.ncbi.nlm.nih.gov/pubmed/26497847","High_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000124422, ENSG00000089685","EFO_0000182","failed","failed term"
"170","NA","NA","CHOLANGIOCARCINOMA","SOCS3,A20","expression",NA,"Patient tissues",26485275,"The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.","study demonstrated that SOCS3 and A20 represent novel prognostic factors for human CCA. patients with low SOCS3 expression or high A20 expression showed a dramatically lower overall survival rate.","https://www.ncbi.nlm.nih.gov/pubmed/26485275","High_Unfavourable,High_Favourable",NA,"NA","56956252","ENSG00000184557, ENSG00000118503","EFO_0005221","failed","failed term"
"171","NA","NA","HEPATOCELLULAR CARCINOMA","Cbl,EGFR","expression,expression",NA,"tissues",26474280,"Peritumoral Cbl is a strong independent prognostic marker after curative resection of hepatocellular carcinoma.","low expression of peritumoral Cbl and EGFR were positively associated with tumor size, microvascular invasion and patients survival after hepatectomy, highlighting the key role of peritumoral liver milieu in HCC progression.","https://www.ncbi.nlm.nih.gov/pubmed/26474280",NA,NA,"NA","56956252","ENSG00000110395, ENSG00000146648","EFO_0000182","failed","failed term"
"172","NA","NA","HEPATOCELLULAR CARCINOMA","DCLK1","expression",NA,"Patient tissues",26468984,"Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.","results support evaluating DCLK1 as a biomarker for detection and as a therapeutic target for eradicating HCC. a marked increase in plasma DCLK1 from patients with HCC.DCLK1 is overexpressed in HCC tumors relative to adjacent normal tissues","https://www.ncbi.nlm.nih.gov/pubmed/26468984","High_Unfavourable",NA,"NA","56956252","ENSG00000133083","EFO_0000182","DCLK1 EXPRESSION NA","pass"
"173","SOREFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","pERK,pAkt","expression,expression",NA,"Patients",26544731,"pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.","pERK+/pAkt- CTCs are most sensitive to sorafenib and an independent predictive factor of PFS in HCC patients treated with sorafenib.","https://www.ncbi.nlm.nih.gov/pubmed/26544731","Positive favourable, Negative favourable",NA,"NA","NA","ENSG00000172071, NA","EFO_0000182","failed","failed drug,failed term"
"174","NA","NA","HEPATOCELLULAR CARCINOMA","TPD52","expression",NA,"Patient tissues,Celllines",26575170,"Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma.","TPD52 is a potential tumor suppressor in HCC. It may be a novel prognostic biomarker and molecular therapy target for HCC. high TPD52 expression was associated with improved overall survival (OS) and disease-free survival (DFS) in HCC patients.","https://www.ncbi.nlm.nih.gov/pubmed/26575170","Low_favourable",NA,"NA","56956252","ENSG00000076554","EFO_0000182","TPD52 EXPRESSION NA","pass"
"175","NA","NA","HEPATOCELLULAR CARCINOMA","NRP1","RNA/expression",NA,"Patient tissues,Celllines",26563279,"High Expression of Neuropilin-1 Associates with Unfavorable Clinicopathological Features in Hepatocellular Carcinoma.","NRP-1 expression may play an important role in the progression of HCC, and that high NRP-1 expression suggests unfavorable clinicopathological characteristics and survival in HCC patients.","https://www.ncbi.nlm.nih.gov/pubmed/26563279","High_Unfavourable",NA,"NA","56956252","ENSG00000099250","EFO_0000182","NRP1 RNA/EXPRESSION NA","pass"
"176","NA","NA","HEPATOCELLULAR CARCINOMA","miR423-5p","RNA/expression",NA,"cellines,tissues",26663009,"Oncogenic role of microRNA-423-5p in hepatocellular carcinoma.","miR423-5p contributed to the tumorigenesis and progression of HCC. It could be a new predictor in HCC patients. miR423-5p was significantly upregulated in HCC compared with nonmalignant tissues, and this upregulation was negatively associated with recurrence-free survival.","https://www.ncbi.nlm.nih.gov/pubmed/26663009","High_Unfavourable",NA,"NA","56956252","NA","EFO_0000182","MIR423-5P RNA/EXPRESSION NA","failed biomarker"
"177","NA","NA","HEPATOCELLULAR CARCINOMA","MEP1A","expression",NA,"Patient tissues,Celllines",26660154,"MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma.","MEP1A is a novel prognostic predictor in HCC and plays an important role in the development and progression of HCC. MEP1A played an important role in regulating cytoskeletal events and induced epithelial-mesenchymal transition in HCC cells. MEP1A messenger RNA levels were significantly elevated in HCC tumor tissues compared with matched adjacent nonneoplastic tissues and nonmalignant liver disease tissues.","https://www.ncbi.nlm.nih.gov/pubmed/26660154","High_Unfavourable",NA,"NA","56956252","ENSG00000112818","EFO_0000182","MEP1A EXPRESSION NA","pass"
"178","NA","NA","HEPATOCELLULAR CARCINOMA","CD90,OCT_4","expression,expression",NA,"Patient tissues,Celllines",26674131,"The prognostic value of combination of CD90 and OCT4 for hepatocellular carcinoma after curative resection.","CD90 and OCT4 are both independent and reliable biomarker for predicting prognosis of HCC patients after hepatic resection. High expression of CD90 or OCT4 predicts a poor prognosis.","https://www.ncbi.nlm.nih.gov/pubmed/26674131","High_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000154096, ENSG00000204531","EFO_0000182","failed","failed term"
"179","NA","NA","HEPATOCELLULAR CARCINOMA","BANCR","RNA/expression",NA,"Patient tissues,Celllines",26758762,"Increased expression of LncRNA BANCR and its prognostic significance in human hepatocellular carcinoma.","BANCR may contribute to HCC initiation and progression and would be used as not only a novel prognostic marker but also a potential therapeutic target for this disease. BANCR expression was remarkably increased in HCC tissues compared with adjacent noncancerous tissues","https://www.ncbi.nlm.nih.gov/pubmed/26758762","High_Unfavourable",NA,"NA","56956252","ENSG00000278910","EFO_0000182","BANCR RNA/EXPRESSION NA","pass"
"180","NA","NA","HEPATOCELLULAR CARCINOMA","GPC3","expression",NA,"Patients",26755876,"Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma.","GPC3 would serve as a useful molecular marker for HCC diagnosis and also as a target for therapeutic intervention in HCC","https://www.ncbi.nlm.nih.gov/pubmed/26755876","High_Unfavourable",NA,"NA","56956252","ENSG00000147257","EFO_0000182","GPC3 EXPRESSION NA","pass"
"181","NA","NA","HEPATOCELLULAR CARCINOMA","CPE","RNA/expression",NA,"Patients",26803519,"Carboxypeptidase E is a prediction marker for tumor recurrence in early-stage hepatocellular carcinoma.","CPE mRNA expression level in HCC can be a useful biomarker for predicting tumor recurrence in HCC patients. The CPE expression level was also significantly correlated with the tumor recurrence for both stage I","https://www.ncbi.nlm.nih.gov/pubmed/26803519",NA,NA,"NA","56956252","ENSG00000109472","EFO_0000182","CPE RNA/EXPRESSION NA","pass"
"182","SOREFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","OCT_1","expression",NA,"Patients",26872727,"Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment.","promising role for intratumoral OCT1 mRNA expression as a prognostic biomarker in therapeutic algorithms in HCC.Intratumoral OCT1 mRNA expression is a significant positive prognostic factor for patients treated with sorafenib. Macrovascular invasion (MVI) was slightly more frequent in patients with low OCT1 mRNA expression","https://www.ncbi.nlm.nih.gov/pubmed/26872727","High_favourable",NA,"NA","NA","ENSG00000143190","EFO_0000182","OCT_1 EXPRESSION NA","failed drug"
"183","NA","NA","HEPATOCELLULAR CARCINOMA","SFRP1","expression",NA,"Patients",26851021,"Loss of SFRP1 Expression Is Associated with Poor Prognosis in Hepatocellular Carcinoma.","SFRP1 may play a role in the development and progression of HCC.Patients with high SFRP1 expression in tumor tissue had a significantly better overall survival rate","https://www.ncbi.nlm.nih.gov/pubmed/26851021","High_favourable",NA,"NA","56956252","ENSG00000104332","EFO_0000182","SFRP1 EXPRESSION NA","pass"
"184","NA","NA","HEPATOCELLULAR CARCINOMA","β-glucosidase 1","expression",NA,"celllines,patients",26849828,"Identification of β-glucosidase 1 as a biomarker and its high expression in hepatocellular carcinoma is associated with resistance to chemotherapy drugs.","Combination of chemo drug with β-glucosidase 1 inhibitor sensitized HCC cells to chemotherapy. β-glucosidase 1 as a HCC biomarker due to its prognosis significance.","https://www.ncbi.nlm.nih.gov/pubmed/26849828","High_Unfavourable",NA,"NA","56956252","NA","EFO_0000182","Β-GLUCOSIDASE 1 EXPRESSION NA","failed biomarker"
"185","NA","NA","HEPATOCELLULAR CARCINOMA","DLC1","protein expression",NA,"tissues",26846339,"DLC-1 is an independent prognostic marker and potential therapeutic target in hepatocellular cancer.","DLC1 could be served as a tumor suppressor gene in the progression especially in the invasion and metastasis of HCC.Evaluation of the expression of DLC-1 might be a good prognostic marker for patients with HCC. DLC-1 expression was found to be negatively correlated with tumor differentiation, TNM stage and lymph node metastasis.","https://www.ncbi.nlm.nih.gov/pubmed/26846339","Low_Unfavourable",NA,"NA","56956252","ENSG00000008226","EFO_0000182","DLC1 PROTEIN EXPRESSION NA","pass"
"186","NA","NA","HEPATOCELLULAR CARCINOMA","CK19,GPC3","Protein expression,Protein expression",NA,"Patients",28977595,"CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.","CK19 and GPC3 expression profiling is an independent prognostic indicator in patients with HCC. CK19+/GPC3+ HCC has the highest risk of multifocality, microvascular invasion, regional lymph node involvement, and distant metastasis","https://www.ncbi.nlm.nih.gov/pubmed/26977595","Positive unfavourable, Positive unfavourable",NA,"NA","56956252","ENSG00000171345, ENSG00000147257","EFO_0000182","failed","failed term"
"187","NA","NA","HEPATOCELLULAR CARCINOMA","SALL4,AFP","expression,expression",NA,"tissues",26973422,"Importance of SALL4 in the development and prognosis of hepatocellular carcinoma.","Patients with higher expression levels of SALL4 and AFP have worse prognosis.","https://www.ncbi.nlm.nih.gov/pubmed/26973422","High_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000101115, ENSG00000081051","EFO_0000182","failed","failed term"
"188","SOREFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","MT1","protein expression",NA,"Patients",27184800,"Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.","MT1 constitute a biomarker adapted for exploring the impact of sorafenib on the redox metabolism of cancer cells.the protein levels of MT1 increase in the serum of some HCC patients receiving sorafenib, and found an association with reduced overall survival.","https://www.ncbi.nlm.nih.gov/pubmed/27184800","Positive unfavourable",NA,"NA","NA","ENSG00000157227","EFO_0000182","MT1 PROTEIN EXPRESSION NA","failed drug"
"189","CISPLATIN","NA","HEPATOCELLULAR CARCINOMA","BCAT1","expression",NA,"celline",27246112,"BCAT1, a key prognostic predictor of hepatocellular carcinoma, promotes cell proliferation and induces chemoresistance to cisplatin.","BCAT1 plays a pathogenic role in HCC by causing cell proliferation and chemoresistance.BCAT1 expression has prognostic significance for the survival of patients with HCC.","https://www.ncbi.nlm.nih.gov/pubmed/27246112","High_Unfavourable",NA,"DB00515","135804801","ENSG00000060982","EFO_0000182","BCAT1 EXPRESSION NA","pass"
"190","NA","NA","HEPATOCELLULAR CARCINOMA","FCN2","expression",NA,"tissues",27177473,"FCN2 inhibits epithelial-mesenchymal transition-induced metastasis of hepatocellular carcinoma via TGF-β/Smad signaling.","FCN2 expression is downregulated in HCC cells and tissues. Low level of FCN2 in HCCs is correlated with aggressive metastatic features, and would be a prognostic factor for overall disease-free survival of HCC patients.","https://www.ncbi.nlm.nih.gov/pubmed/27177473","High_Unfavourable",NA,"NA","56956252","ENSG00000160339","EFO_0000182","FCN2 EXPRESSION NA","pass"
"191","NA","NA","HEPATOCELLULAR CARCINOMA","MBD2","expression",NA,"tissues",27315121,"MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection.","MBD2 expression was elevated in HCC tissue, which suggesting MBD2 as a candidate prognostic marker of HCC.","https://www.ncbi.nlm.nih.gov/pubmed/27315121","High_Unfavourable",NA,"NA","56956252","ENSG00000134046","EFO_0000182","MBD2 EXPRESSION NA","pass"
"192","NA","NA","COMBINED HEPATOCELLUAR-CHOLANGIOCARCINOMA","DCP, AFP,CA-199","serum-level",NA,"Patients",32169133,"Diagnostic Value of Serum Biomarkers in Combined Hepatocelluar-Cholangiocarcinoma.","DCP, AFP and CA-199 have diagnostic value for cHCC-CC, and the combination of DCP, AFP and CA-199 is useful for assisting diagnosis before histological examination. 
The levels of DCP, AFP and CA-199 were clearly elevated in the cHCC-CC group relative to controls","https://www.ncbi.nlm.nih.gov/pubmed/32169133","High_Unfavourable,High_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000159640, ENSG00000081051, NA","EFO_0000313","failed","failed term"
"193","SORAFENIB","Multikinase","HEPATOCELLULAR CARCINOMA","APEX1","RNA/protein expression",NA,"Patients",32167932,"APEX1 is a novel diagnostic and prognostic biomarker for hepatocellular carcinoma.","The APEX1 mRNA and protein levels were significantly higher in HCC than adjacent normal liver tissues.  High APEX1 expression correlated with resistance to sorafenib and anti-programmed death 1 (PD-1) therapies in HCC patients, and it associated with poorer overall survival, disease-specific survival, progression-free survival, and relapse-free survival in early- and advanced-stage HCC patients.","https://www.ncbi.nlm.nih.gov/pubmed/32167932","High_Unfavourable/High_Unfavourable",NA,"DB00398","406563","ENSG00000100823","EFO_0000182","APEX1 RNA/PROTEIN EXPRESSION NA","pass"
"194","NA","NA","HEPATOCELLULAR CARCINOMA","mLST8","expression",NA,"Patient tissues",32157528,"Enhanced mLST8 Expression Correlates with Tumor Progression in Hepatocellular Carcinoma."," mLST8 level was dramatically higher in HCC specimens than in adjacent non-tumor specimens","https://www.ncbi.nlm.nih.gov/pubmed/32157528","High_Unfavourable , chinese population",NA,"NA","56956252","ENSG00000167965","EFO_0000182","MLST8 EXPRESSION NA","pass"
"195","NA","NA","HEPATOCELLULAR CARCINOMA","sAxl","serum-level",NA,"Patients",32138467,"Soluble Axl Is a Novel Diagnostic Biomarker of Hepatocellular Carcinoma in Chinese Patients with Chronic Hepatitis B Virus Infection.","sAxl were high expression in patients with HCC. sAxl is a candidate serum marker for diagnosing HCC.","https://www.ncbi.nlm.nih.gov/pubmed/32138467","High_Unfavourable",NA,"NA","56956252","NA","EFO_0000182","SAXL SERUM-LEVEL NA","failed biomarker"
"196","NA","NA","LIVER CANCER","SPATS2","expression",NA,"Patient tissues",32118724,"Comprehensive evaluation of SPATS2 expression and its prognostic potential in liver cancer.","SPATS2 expression could be a novel diagnostic and prognostic biomarker in liver cancer. patients with high SPATS2 expression have an apparently shorter overall survival (OS, P < .0001) and relapse-free survival (RFS, P < .0001).","https://www.ncbi.nlm.nih.gov/pubmed/32118724","High_Unfavourable",NA,"NA","56956252","ENSG00000123352","MONDO_0002691","SPATS2 EXPRESSION NA","pass"
"197","NA","NA","HEPATOCELLULAR CARCINOMA","BICD1","expression",NA,"Patient tissues,Celllines",32088084,"BICD1 functions as a prognostic biomarker and promotes hepatocellular carcinoma progression.","BICD1 knockdown abolished hypoxia-induced HCC cell proliferation, migration and invasion. In conclusion, we provide the first evidence to support that BICD1 functions as a predictor for the prognosis of HCC and may serve as a promising therapeutic target for further HCC treatment.","https://www.ncbi.nlm.nih.gov/pubmed/32088084","High_Unfavourable",NA,"NA","56956252","ENSG00000151746","EFO_0000182","BICD1 EXPRESSION NA","pass"
"198","NA","NA","HEPATOCELLULAR CARCINOMA","OPN","serum-level",NA,"Patients",32043608,"OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis.","the serum OPN level increased significantly in HCC even in tumors of less than 2 cm.","https://www.ncbi.nlm.nih.gov/pubmed/32043608","High_Unfavourable",NA,"NA","56956252","ENSG00000118785","EFO_0000182","OPN SERUM-LEVEL NA","pass"
"199","NA","NA","HEPATOCELLULAR CARCINOMA","MITD1","expression",NA,"Patient, tissues",32007795,"Prognostic biomarker MITD1 and its correlation with immune infiltrates in hepatocellular carcinoma (HCC).","MITD1 may be able to serve as a predictor for human HCC prognosis.","https://www.ncbi.nlm.nih.gov/pubmed/32007795","High_Unfavourable",NA,"NA","56956252","ENSG00000158411","EFO_0000182","MITD1 EXPRESSION NA","pass"
"200","NA","NA","HEPATOCELLULAR CARCINOMA","HCRP1, ID4 , GPC3","expression,expression,expression",NA,"Patient tissues",31949663,"HCRP1, ID4 and Glypican-3: an optimal panel of biomarkers for diagnosis of hepatocellular carcinoma.","HCRP1 and ID4 represent potentially novel valuable biomarkers for distinguishing HCC from benign liver nodules, and it is recommended to use the combination of HCRP1, ID4 and GPC-3 as a panel in HCC differentiation estimation.","https://www.ncbi.nlm.nih.gov/pubmed/31949663","High_Unfavourable,High_Unfavourable,High_Unfavourable",NA,"NA","56956252","ENSG00000155975, ENSG00000172201, ENSG00000147257","EFO_0000182","failed","failed term"
